Biotelemetry 10-K 22 Feb 16 2015 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2015	Feb. 17, 2016	Jun. 30, 2015
Document and Entity Information
Entity Registrant Name	BioTelemetry, Inc.
Entity Central Index Key	1,574,774
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Public Float			$ 171,648,773
Entity Common Stock, Shares Outstanding		27,388,563
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	FY

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets:
Cash and cash equivalents	$ 18,986	$ 20,007
Accounts receivable, net of allowance for doubtful accounts of $11,185 and $10,347 at December 31, 2015 and 2014, respectively	15,179	15,184
Other accounts receivable, net of allowance for doubtful accounts of $416 and $315 at December 31, 2015 and 2014, respectively	8,997	9,362
Inventory	2,378	2,566
Prepaid expenses and other current assets	1,505	2,081
Total current assets	47,045	49,200
Property and equipment, net	25,554	21,703
Intangible assets, net	19,981	22,720
Goodwill	29,831	29,596
Other assets	1,732	1,153
Total assets	124,143	124,372
Current liabilities:
Accounts payable	8,496	13,195
Accrued liabilities	11,230	18,460
Current portion of capital leases	287	480
Current portion of long-term debt	1,250	938
Deferred revenue	2,625	2,248
Total current liabilities	23,888	35,321
Deferred tax liability	1,233	987
Long-term portion of capital leases	101	388
Long-term debt	21,944	22,935
Deferred rent	1,051	1,065
Total liabilities	48,217	60,696
Stockholders' equity:
Common stock-$.001 par value as of December 31, 2015 and 2014; 200,000,000 shares authorized as of December 31, 2015 and 2014; 27,277,939 and 26,693,248 shares issued and outstanding at December 31, 2015 and 2014 , respectively	27	27
Paid-in capital	272,070	267,236
Accumulated other comprehensive loss	(12)
Accumulated deficit	(196,159)	(203,587)
Total stockholders' equity	75,926	63,676
Total liabilities and stockholders' equity	$ 124,143	$ 124,372

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
CONSOLIDATED BALANCE SHEETS
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 11,185	$ 10,347
Other receivable, allowance for doubtful accounts (in dollars)	$ 416	$ 315
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	200,000,000	200,000,000
Common stock, shares issued	27,277,939	26,693,248
Common stock, shares outstanding	27,277,939	26,693,248

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Revenues:
Healthcare									$ 145,963	$ 133,178	$ 100,386
Research services									21,853	19,744	20,329
Technology									10,697	13,656	8,786
Total revenues	$ 46,774	$ 43,492	$ 44,812	$ 43,435	$ 43,653	$ 43,113	$ 42,650	$ 37,162	178,513	166,578	129,501
Cost of revenues:
Healthcare									51,693	54,942	34,179
Research									12,728	10,646	11,317
Technology									7,535	7,526	4,935
Total cost of revenues									71,956	73,114	50,431
Gross profit	28,264	26,337	26,733	25,223	24,529	23,678	23,613	21,644	106,557	93,464	79,070
Operating expenses:
General and administrative									47,882	45,131	36,569
Sales and marketing									27,936	28,805	26,275
Bad debt expense									8,047	9,347	7,787
Research and development									7,111	7,396	7,338
Other charges	1,601	1,392	1,210	1,860	2,073	1,045	1,000	2,980	6,063	7,098	7,982
Total operating expenses									97,039	97,777	85,951
Income (loss) from operations	3,458	3,006	2,585	469	(702)	486	(401)	(3,696)	9,518	(4,313)	(6,881)
Interest and other loss, net									(1,622)	(7,793)	(223)
Income (loss) before income taxes									7,896	(12,106)	(7,104)
(Provision for) benefit from income taxes									(468)	2,313	(215)
Net income (loss)	$ 2,848	$ 2,478	$ 2,171	$ (69)	$ (1,654)	$ (29)	$ (3,988)	$ (4,122)	7,428	(9,793)	(7,319)
Other comprehensive loss:
Foreign currency translation loss									(12)
Comprehensive income (loss)									$ 7,416	$ (9,793)	$ (7,319)
Net income (loss) per common share:
Basic (in dollars per share)	$ 0.10	$ 0.09	$ 0.08	$ 0	$ (0.06)	$ 0	$ (0.15)	$ (0.16)	$ 0.27	$ (0.37)	$ (0.29)
Diluted (in dollars per share)	$ 0.10	$ 0.08	$ 0.08	$ 0	$ (0.06)	$ 0	$ (0.15)	$ (0.16)	$ 0.26	$ (0.37)	$ (0.29)
Weighted average number of common shares outstanding:
Basic (in shares)									27,116,300	26,444,626	25,543,646
Diluted (in shares)									29,089,211	26,444,626	25,543,646

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Operating activities
Net income ( loss)	$ 7,428	$ (9,793)	$ (7,319)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Provision for doubtful accounts	8,047	9,347	7,787
Depreciation	8,987	8,858	9,978
(Decrease) increase in deferred rent	(14)	355	(215)
Deferred income tax expense (benefit)	245	(2,499)	53
Stock-based compensation	4,952	4,037	3,303
Amortization of intangibles	3,501	3,692	2,340
Accretion of debt discount and amortization of deferred charges	259
Loss on extinguishment of debt		203
Changes in operating assets and liabilities:
Accounts receivable	(7,677)	(12,795)	(4,597)
Inventory	188	299	340
Prepaid expenses and other assets	(3)	(128)	(637)
Accounts payable	(4,699)	47	2,369
Accrued and other liabilities	(464)	788	(2,143)
Liability associated with the Civil Investigative Demand	(6,400)	6,400
Net cash provided by operating activities	14,350	8,811	11,259
Investing activities
Acquisition of business, net of cash acquired		(14,100)
Purchases of property and equipment and investment in internally developed software	(13,600)	(12,781)	(8,169)
Net cash used in investing activities	(13,600)	(26,881)	(8,169)
Financing activities
(Payments) proceeds related to the exercising of stock options and vesting of RSUs	(353)	1,051	847
Issuance of long-term debt		41,838
Principal payments of long-term debt	(938)	(26,434)
Principal payments on capital lease obligations	(480)	(529)	(84)
Net cash (used in) provided by financing activities	(1,771)	15,926	763
Net (decrease) increase in cash and cash equivalents	(1,021)	(2,144)	3,853
Cash and cash equivalents - beginning of period	20,007	22,151
Cash and cash equivalents - end of period	18,986	20,007	22,151
Supplemental disclosure of cash flow information
Cash paid for interest	1,044	856	132
Cash paid for taxes	$ 384	$ 148	$ 112

CONSOLIDATED STATEMENTS OF SHAR

CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Paid-in Capital	Accumulated Other Comprehensive Loss	Accumulated Deficit	Total
Balance at Dec. 31, 2012	$ 25	$ 256,448		$ (186,475)	$ 69,998
Balance (in shares) at Dec. 31, 2012	25,189,340
Increase (Decrease) in Shareholders' Equity
Exercise of stock options and purchase of shares related to the employee stock purchase plan	$ 1	846			847
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	348,681
Stock based compensation		3,303			3,303
Stock based compensation (in shares)	274,733
Net income (loss)				(7,319)	(7,319)
Balance at Dec. 31, 2013	$ 26	260,597		(193,794)	66,829
Balance (in shares) at Dec. 31, 2013	25,812,754
Increase (Decrease) in Shareholders' Equity
Exercise of stock options and purchase of shares related to the employee stock purchase plan	$ 1	1,050			1,051
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	503,036
Stock based compensation		4,037			4,037
Stock based compensation (in shares)	195,437
Issuance of stock related to prior year business combinations		1,552			1,552
Issuance of stock related to prior year business combinations (in shares)	182,021
Net income (loss)				(9,793)	(9,793)
Balance at Dec. 31, 2014	$ 27	267,236		(203,587)	63,676
Balance (in shares) at Dec. 31, 2014	26,693,248
Increase (Decrease) in Shareholders' Equity
Exercise of stock options and purchase of shares related to the employee stock purchase plan		1,222			1,222
Exercise of stock options and purchase of shares related to the employee stock purchase plan (in shares)	268,448
Stock based compensation		4,952			4,952
Stock based compensation (in shares)	451,116
RSUs withheld to cover taxes		(1,575)			(1,575)
RSUs withheld to cover taxes ( in shares )	(167,090)
Issuance of stock related to prior year business combinations		235			235
Issuance of stock related to prior year business combinations (in shares)	32,217
Currency translation adjustment			$ (12)		(12)
Net income (loss)				7,428	7,428
Balance at Dec. 31, 2015	$ 27	$ 272,070	$ (12)	$ (196,159)	$ 75,926
Balance (in shares) at Dec. 31, 2015	27,277,939

Organization and Description of

Organization and Description of Business	12 Months Ended
	Dec. 31, 2015
Organization and Description of Business
Organization and Description of Business	1. Organization and Description of Business BioTelemetry, Inc. ("BioTelemetry," "Company", "we," "our" or "us"), a Delaware corporation, provides cardiac monitoring services, cardiac monitoring device manufacturing and central core laboratory services. We operate under three reportable segments: (1) Healthcare, (2) Technology and (3) Research. The Healthcare segment is focused on the diagnosis and monitoring of cardiac arrhythmias, or heart rhythm disorders. We offer cardiologists and electrophysiologists with a full spectrum of solutions which provides them with a single source of cardiac monitoring services. These services range from the differentiated MCT service marketed as Mobile Cardiac Outpatient Telemetry TM ("MCOT™") or External Cardiac Ambulatory Telemetry ("ECAT"), to wireless and trans telephonic event, Holter, Pacemaker and International Normalized Ratio ("INR") monitoring. Since we became focused on cardiac monitoring in 1999, we have developed a proprietary integrated patient management platform that incorporates a wireless data transmission network, Food and Drug Administration ("FDA") cleared algorithms and medical devices and 24-hour monitoring service centers. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. In June 2014, we completed the acquisition of the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. RadCore is included in the Research segment. In April 2014, we completed the acquisition of substantially all of the assets of Biomedical Systems Corporation ("BMS") cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services. BMS is primarily included in the Healthcare segment. In January 2014, we completed the acquisition of Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc. and Universal Medical Laboratory, Inc. (together, the "Mednet entities"). Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices. Mednet entities are included in the Healthcare and Technology segment. As of July 31, 2013, we reorganized to create a holding company structure. CardioNet, Inc., which was previously the public company, became a wholly-owned subsidiary of a newly formed entity, BioTelemetry, Inc., a Delaware corporation, and all the outstanding shares of CardioNet, Inc. were exchanged, on an one-for-one basis, for shares of BioTelemetry, Inc. Our new holding company began trading on August 1, 2013 on The NASDAQ Global Select Market under our same symbol "BEAT."

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2015
Summary of Significant Accounting Policies
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The accompanying consolidated financial statements include the accounts of BioTelemetry and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation. Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates. Fair Value of Financial Instruments The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. Our financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable, short-term and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For long-term debt, based on the borrowing rates currently available, the fair value was determined to be $24,063 as of December 31, 2015. This is equal to the nominal value, carrying value exclusive of debt discount and deferred charges. We did not have any Level 3 assets or liabilities for the periods ended December 31, 2015 and 2014. Cash and Cash Equivalents Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk. Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable related to the Healthcare segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record an allowance for doubtful accounts based on the aging of receivables using historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows. Other receivables related to the Technology and Research segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and aging of the account. We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Healthcare segment, we wrote off $7,082 and $6,494 of receivables for the years ended December 31, 2015 and 2014, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write offs in the Technology and Research segments. Additionally, we recorded bad debt expense of $8,047, $9,347 and $7,787 for the years ended December 31, 2015, 2014 and 2013, respectively. Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased. At December 31, 2015, 2014 and 2013, one customer, Medicare, accounted for 13% 16%, and 15%, respectively, of our gross accounts receivable. Inventory Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Management reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market. Property and Equipment Property and equipment is recorded at cost, except for assets acquired in business combinations. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred. Impairment of Long-Lived Assets The carrying value of long-lived assets, other than goodwill and indefinite-lived intangible assets, is evaluated when events or changes in circumstances indicate the carrying value may not be recoverable or the useful life has changed. We consider historical performance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected discounted future cash flows is less than the assets' carrying value. Equity Method Investments We account for investments using the equity method of accounting if the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company's ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee's board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at cost in the consolidated balance sheets under Other assets and adjusted for dividends received and our share of the investee's earnings or losses together with other-than-temporary impairments which are recorded through Interest and other loss, net in the consolidated statements of operations. In December 2015, we acquired approximately 29% of the outstanding stock of Well Bridge Health, Inc. through the conversion of an outstanding note receivable and the related accrued interest. The investment is accounted for under the equity method. As of December 31, 2015, $1,100 was recorded under Other assets. The equity method basis difference of $891 was allocated to equity method goodwill. For the year ended December 31, 2015, no dividends were received and our share of the investee's earnings were not material. Goodwill and Acquired Intangible Assets Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other , goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded. For the purpose of performing our goodwill impairment analysis in 2015, we consider our business to be comprised of three reporting units: Healthcare, Technology and Research. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data from publicly traded companies that are similar to us. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units. Acquired intangible assets are recorded at fair value on the acquisition date. The estimated fair values and useful lives of intangible assets are determined by assessing many factors including estimates of future operating performance and cash flows of the acquired business, the characteristics of the intangible assets and the experience of the acquired business. Independent appraisal firms may assist with the valuation of acquired assets. The impairment test for indefinite-lived intangibles other than goodwill consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset. We estimate the fair value of the indefinite-lived intangibles using the relief from royalty method. Revenue Recognition We recognize approximately 82% of our total revenue from patient monitoring services in our Healthcare segment. We receive a significant portion of this revenue from third party commercial payors and governmental entities. We also receive reimbursement directly from patients through co-pay, deductibles and self-pay arrangements. Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If we do not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service has been completed. For the years ended December 31, 2015, 2014 and 2013, revenue from Medicare as a percentage of total revenue was 34%, 32% and 35%, respectively. Revenue in our Technology segment is received from the sale of products, product repair and supplies which are recognized when shipped, or as service is completed. Research revenue includes revenue for core laboratory services. Our Research revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed. For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor-specific or third-party evidence is unavailable. We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities. Research and Development Costs Research and development costs are charged to expense as incurred. Net Income (loss) We compute net income (loss) per share in accordance with ASC 260, Earnings Per Share . The following summarizes the potential outstanding common stock as of the end of each period: December 31, 2015 December 31, 2014 December 31, 2013 Employee stock purchase plan estimated share options outstanding Common stock options and restricted stock units ("RSUs") outstanding Common stock available for grant Common stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common shares, including stock options and RSUs. The following table presents the calculation of historical basic and diluted net income (loss) per share: Year Ended December 31, 2015 2014 2013 (in thousands, except per share amounts) Numerator: Net income (loss) $ $ ) $ ) Denominator: Weighted average shares used in computing basic net income (loss) per share Potential dilutive common shares due to dilutive stock option and restricted stock units — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares used in computing diluted net income (loss) per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) per share: Basic net income (loss) per share $ $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income (loss) per share $ $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ If the outstanding vested options or RSUs were exercised or converted into common stock, the result would be anti-dilutive for the years ended December 31, 2014 and 2013. Accordingly, basic and diluted net loss per share are the same for the years ended December 31, 2014 and 2013. Additionally, certain stock options, which are priced higher than the market price of our shares as of December 31, 2015, would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income (loss) per share. These options could become dilutive in future periods. Stock-Based Compensation ASC 718, Compensation—Stock Compensation , addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measure the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. The compensation expense associated with performance stock units is recognized over the period between when the performance conditions are deemed probable of achievement and when the awards are vested. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees . Income Taxes We account for income taxes under the liability method, as described in ASC 740, Income Taxes . Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged to be more likely than not. Segment Information ASC 280, Segment Reporting , establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance. We report our business under three segments: Healthcare, Technology and Research. The segments were renamed in the fourth quarter of 2015 to provide a more accurate description of the business conducted by the segment. There is no change to the composition of our reportable segments as a result of the name change. The Healthcare segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders in a health care setting. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research segment includes our operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and device sales. Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In November 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes . The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet. Previously, deferred taxes have been separated into current and noncurrent. We have elected to early adopt this standard at December 31, 2015 and have applied this change in accounting principle retrospectively. As a result of our retrospective adoption, $271 of deferred tax assets have been reclassified from Prepaid and other current assets to Deferred tax liability on our December 31, 2014 Consolidated Balance Sheet. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs . The standard requires debt issuance costs to be presented on the balance sheet as a direct reduction of the carrying value of the associated debt liability, consistent with the presentation of debt discounts. Previously, debt issuance costs have been presented as a deferred asset. The recognition and measurement requirements will not change as a result of this guidance. We have elected to early adopt this standard at December 31, 2015 and have applied this change in accounting principle retrospectively. As a result of our retrospective adoption, $135 of debt issuance costs have been reclassified from Other assets to Long-term debt on our December 31, 2014 Consolidated Balance Sheet. Accounting Pronouncements Not Yet Adopted In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The standard will require inventory to be measured at the lower of cost or net realizable value. The guidance will not apply to inventories for which cost is determined using the last-in, first-out method or the retail inventory method. The standard is effective for annual and interim reporting periods beginning after December 15, 2016. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements. In May 2014 and August 2015, the FASB issued ASU 2014-09 and 2015-14, respectively, Revenue from Contracts with Customers , which provides guidance for revenue recognition. The standards will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which a company expects to receive in exchange for those goods or services. The standards also requires new, expanded disclosures regarding revenue recognition. The standards will be effective January 1, 2018 with early adoption permissible beginning January 1, 2017. We are currently evaluating the transition method we will elect and the impact the adoption of this standard will have on our consolidated financial statements.

Business Combinations

Business Combinations	12 Months Ended
	Dec. 31, 2015
Business Combinations
Business Combinations	3. Business Combinations RadCore Lab, LLC On June 3, 2014, we acquired the assets of RadCore Lab, LLC ("RadCore"), an imaging core lab serving the biopharmaceutical and medical device research market. This acquisition broadens our offerings and adds new oncology, musculoskeletal and neurological imaging capabilities, supported by a state-of-the-art, cloud-based analysis platform. We paid $400 in cash at closing and 22,513 shares of our common stock, valued at $200 at closing. While this acquisition provides growth potential, the acquisition of RadCore did not have a material effect on our financial condition, results of operations or cash flows. Biomedical Systems Corporation On April 3, 2014, we completed the acquisition of substantially all of the assets of Biomedical Systems Corporation's ("BMS") cardiac event monitoring, Holter monitoring and mobile telemetry monitoring services. The acquisition gave us access to internally developed Holter software and to established customer relationships. We paid $8,000 in cash at closing and 62,859 shares of our common stock, valued at $650 at closing. While the acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition, BMS did not have a material effect on our results of operations or cash flows. The purchase price allocation was completed in the first quarter of 2015. The amounts below represent the final fair value of assets acquired. Fair value of assets acquired: Property and equipment $ Goodwill Intangible assets ​ ​ ​ ​ ​ Net assets acquired $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The allocation of intangible assets is comprised of the following: Estimated Useful Life (Years) Fair Value Customer relationships $ Technology Covenants not to compete ​ ​ ​ ​ ​ ​ ​ ​ Total intangible assets $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Goodwill recorded in connection with this acquisition is attributable to synergies expected to arise from cost savings opportunities. All of the recorded goodwill is included in the Healthcare segment. Mednet Healthcare Technologies, Inc. On January 31, 2014, we acquired Mednet Healthcare Technologies, Inc., Heartcare Corporation of America, Inc., Universal Medical, Inc. and Universal Medical Laboratory, Inc. (together, "Mednet"). Mednet provides cardiac monitoring services and is an original equipment manufacturer of cardiac monitoring devices. The acquisition gave us access to established customer relationships. Upon the closing of the transaction, we acquired all of the issued and outstanding capital stock, and Mednet became a wholly-owned subsidiary. We paid $5,500 in cash at closing and 128,866 shares of our common stock, valued at $940 at closing. In addition, as a result of the acquisition, we assumed indebtedness from Mednet in the aggregate amount of $9,720, including interest. The acquisition has been included within the consolidated results of operations and financial condition from the date of the acquisition. The purchase price allocation was completed in the first quarter of 2015. The amounts below represent the final fair value of assets acquired. Fair value of assets acquired: Cash and cash equivalents $ ) Accounts receivable Inventory Property and equipment Goodwill Intangible assets Other assets ​ ​ ​ ​ ​ Total assets acquired Liabilities assumed: Accounts payable Accrued expenses Other liabilities Long-term debt, capital leases, note payable and related interest ​ ​ ​ ​ ​ Total liabilities assumed ​ ​ ​ ​ ​ Net assets acquired $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The allocation of intangible assets is comprised of the following: Estimated Useful Life (Years) Fair Value Customer relationships $ Technology Covenants not to compete Indefinite-lived trade name ​ ​ ​ ​ ​ ​ ​ ​ Total intangible assets $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Goodwill recorded in connection with this acquisition is attributable to the assembled workforce and synergies expected to arise from cost savings opportunities. All of the recorded goodwill is included in the Healthcare segment. The unaudited pro forma information below presents combined results of operations as if the acquisition had occurred at the beginning of the periods presented instead of January 31, 2014. The pro forma information presented below does not include anticipated synergies or certain other expected benefits of the acquisition and should not be used as a predictive measure of our future results of operations. Mednet contributed $23,355 in revenue for the year ended December 31, 2014. December 31, Unaudited pro forma information 2014 2013 Revenue $ $ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net loss per common share: Basic and Diluted ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average number of shares: Basic ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Inventory

Inventory	12 Months Ended
	Dec. 31, 2015
Inventory
Inventory	4. Inventory Inventory consists of the following: December 31, 2015 2014 Raw materials and supplies $ $ Finished goods ​ ​ ​ ​ ​ ​ ​ ​ Total inventories $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Inventories, which include purchased parts, materials, direct labor and applied manufacturing overhead, are stated at the lower of cost or market, with cost determined by use of the first-in, first-out method.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2015
Property and Equipment
Property and Equipment	5. Property and Equipment Property and equipment consists of the following: December 31, Estimated Useful Life (Years) 2015 2014 Cardiac monitoring devices, device parts and components 3 - 5 $ $ Computers and purchased software 3 - 5 Equipment, tools and molds 3 - 5 Furniture and fixtures 7 Leasehold improvements Life of lease Capital leases 3 - 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total property and equipment, at cost Less accumulated depreciation ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total property and equipment, net $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Depreciation expense associated with property and equipment, inclusive of amortization of assets recorded under capital leases, was $8,987, $8,858 and $9,978, for the years ended December 31, 2015, 2014 and 2013, respectively.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets
Goodwill and Intangible Assets	6. Goodwill and Intangible Assets Goodwill was recognized at the time of our acquisitions. The carrying amount of goodwill as of December 31, 2015 and 2014 was $29,831 and $29,596, respectively. The increase in goodwill during the year ended December 31, 2015 relates to the finalization of the purchase price allocation for the Mednet acquisition. The changes in the carrying amounts of goodwill by segment were as follows: Reporting Segment Healthcare Research Technology Total Balance at December 31, 2014 $ $ $ $ Goodwill acquired during the year — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2015 $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The gross carrying amounts and accumulated amortization of our intangible assets as of December 31, 2015 and 2014 are as follows: December 31, Estimated Useful Life (Years) 2015 2014 Customer relationships 5 - 15 $ $ Technology including internally developed software 3 - 5 Signed backlog 1 - 4 Unsigned backlog 4 Covenants not to compete 5 - 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total intangible assets, gross ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer relationships accumulated amortization ) ) Proprietary technology accumulated amortization ) ) Signed backlog accumulated amortization ) ) Unsigned backlog accumulated amortization ) ) Covenants not to compete accumulated amortization ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total accumulated amortization ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Indefinite-lived trade names Total intangible assets, net $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The estimated amortization expense for the next five years and thereafter is summarized as follows at December 31, 2015: 2016 $ 2017 2018 2019 2020 Thereafter ​ ​ ​ ​ ​ Total estimated amortization $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization expense for the years ended December 31, 2015, 2014, and 2013 was $3,501, $3,692 and $2,340, respectively. At December 31, 2015, 2014 and 2013, we performed our required annual impairment test of goodwill and indefinite lived intangibles. Based on these impairment tests, we determined that there was no impairment.

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2015
Accrued Expenses
Accrued Expenses	7. Accrued Expenses Accrued expenses consisted of the following: December 31, 2015 2014 Accrued compensation $ $ Accrued professional fees Accrued purchases Accrued restructuring costs Other ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Other Charges

Other Charges	12 Months Ended
	Dec. 31, 2015
Other Charges
Other Charges	8. Other Charges We account for expenses associated with exit or disposal activities in accordance with ASC 420, Exit or Disposal Cost Obligations, and record the expenses in Other charges in our statement of operations, and record the related accrual in the Accrued expenses line of our balance sheet. We account for expenses associated with integration and certain litigation as Other charges as incurred. These costs are primarily disclosed as Legal fees and Professional fees below. These expenses were primarily a result of legal fees related to patent litigation and the Civil Investigative Demand, as well as activities surrounding our acquisitions. A summary of these expenses is as follows: Year ended December 31, 2015 2014 2013 Legal fees $ $ $ Severance and employee related costs Professional fees Expenses related to facility closure — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Shareholders' Equity

Shareholders' Equity	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity
Stockholders' Equity	9. Shareholders' Equity Common Stock As of December 31, 2014 and 2013, we were authorized to issue 200,000,000 shares of common stock. As of December 31, 2015 and 2014, we had 27,277,939 and 26,693,248 shares outstanding, respectively. Preferred Stock We maintain an unregistered blank check preferred stock class. As of December 31, 2015 and 2014, there were no shares authorized and outstanding. Stock-Based Compensation 2008 Equity Incentive Plan Our 2008 Equity Incentive Plan (the 2008 Option Plan) became effective on March 18, 2008. The Plan permits our Board of Directors to grant incentive stock options to employees and non-qualified stock options, restricted stock, performance stock and other stock-based incentive awards to officers, directors, employees and consultants. On that date, we began granting options to purchase shares of common stock to employees, executives, directors and consultants. Under the terms of the 2008 Option Plan, all available shares in the 2003 Option Plan's share reserve automatically rolled into the 2008 Option Plan. Any cancellations or forfeitures of granted options under the 2003 Option Plan also automatically roll into the 2008 Option Plan. Beginning on January 1, 2009, and each year thereafter, the number of options available to be granted under the plan will increase by the lesser of 4% of the total number of common shares outstanding or 1,500,000 shares. Options granted under the 2008 Option Plan have exercise prices not less than the fair market value at the date of grant and have an expiration date of no greater than ten years from the date of grant. There is no predetermined vesting schedule provided in the 2008 Option Plan, and vesting is determined by the Board of Directors on the date of grant. The 2008 Equity Incentive Plan has 2,050,388 shares available for grant as of December 31, 2015. Stock option activity is summarized for the years ended December 31, 2015, 2014 and 2013 as follows: Number of Shares Weighted Average Exercise Price Options outstanding as of December 31, 2012 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Cancelled ) $ Exercised ) $ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding as of December 31, 2013 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Cancelled ) $ Exercised ) $ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding as of December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Cancelled ) $ Exercised ) $ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding as of December 31, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ A summary of total outstanding stock options as of December 31, 2015 is as follows: Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $0.70 - $7.50 $ $ $7.51 - $15.00 $ $ $15.01 - $22.50 $ $ $22.51 - $31.18 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $0.70 - $31.18 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The table below summarizes certain additional information with respect to our options: (In thousands) 2015 2014 2013 Aggregate intrinsic value of options outstanding at year-end $ $ $ Aggregate intrinsic value of options exercisable at year-end Aggregate intrinsic value of options exercised during the year Total cash received from the exercise of stock options for the year ended December 31, 2015, 2014 and 2013 was $291, $529 and $467, respectively. The tax benefit was fully reserved for through a tax valuation allowance. Restricted stock units activity is summarized for the years ended December 31, 2015, 2014 and 2013 as follows: Number of Shares Weighted Average Grant Date Fair Value Restricted stock outstanding as of December 31, 2012 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited ) $ Vested ) $ ​ ​ ​ ​ ​ ​ ​ ​ Restricted stock outstanding as of December 31, 2013 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited ) $ Vested ) $ ​ ​ ​ ​ ​ ​ ​ ​ Restricted stock outstanding as of December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited ) $ Vested ) $ ​ ​ ​ ​ ​ ​ ​ ​ Restricted stock outstanding as of December 31, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ In addition, a summary of total outstanding RSUs as of December 31, 2015 is as follows: Range of Grant Price RSUs Outstanding $2.16 - $6.75 $6.76 - $9.75 ​ ​ ​ ​ ​ $2.16 - $9.75 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Performance stock units ("PSUs") activity is summarized for the years ended December 31, 2015 and 2014 as follows: Number of Shares Weighted Average Grant Date Fair Value Performance stock outstanding as of December 31, 2013 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited — — Vested — — ​ ​ ​ ​ ​ ​ ​ ​ Performance stock outstanding as of December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted — — Forfeited ) $ Vested — — ​ ​ ​ ​ ​ ​ ​ ​ Performance stock outstanding as of December 31, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Stock compensation expense is only recognized for outstanding PSUs where the performance conditions are deemed probable for achievement. For the years ended December 31, 2015 and 2014, we incurred PSU expenses of $711 and $0, respectively. We expect to recognize $444 of stock compensation expense over the year ended December 31, 2016 related to outstanding PSUs. During the year ended December 31, 2015, 200,000 performance stock options ("PSOs") were granted. There were no forfeitures or vesting of PSOs during the year ended December 31, 2015. Stock compensation expense will only be recognized once the performance conditions of the outstanding PSOs have been met. No stock compensation expense has been recognized related to the PSOs during the year ended December 31, 2015. We estimate the fair value of our share-based awards to employees and directors using the Black-Scholes option valuation model. The Black-Scholes option valuation model requires the use of certain subjective assumptions. The most significant of these assumptions are the estimates of the expected volatility of the market price of our stock and the expected term of the award. We base our estimates of expected volatility on the historical average of our stock price. The expected term represents the period of time that stock-based awards granted are expected to be outstanding. Other assumptions used in the Black-Scholes option valuation model include the risk-free interest rate and expected dividend yield. The risk-free interest rate for periods pertaining to the contractual life of each option is based on the U.S. Treasury yield of a similar duration in effect at the time of grant. We have never paid, and do not expect to pay, dividends in the foreseeable future. The fair value of our stock-based awards was estimated at the date of grant using the following weighted average assumptions: Year Ended December 31, 2015 2014 2013 Expected volatility % % % Expected term (in years) Weighted average risk-free interest rate % % % Expected dividends % % % Weighted average grant date fair value per option $ $ $ Weighted average grant date fair value per RSU $ $ $ Based on our historical experience of options and restricted stock units that cancel before becoming fully vested, we have assumed an annualized forfeiture rate of 9.2% for options, 6.7% for restricted stock units and 0.0% for performance stock units. Under the true-up provision of ASC 718, we will record additional expense if the actual forfeiture rate is lower than estimated, and will record a recovery of prior expense if the actual forfeiture rate is higher than estimated. The total compensation cost of options granted but not yet vested at December 31, 2015, 2014 and 2013 was approximately $3,608, $2,744 and $2,644, respectively, which is expected to be recognized over a weighted average period of 2.66 years, 2.68 years and 2.14 years, respectively. Unvested stock options as of December 31, 2015 and 2014 were 837,915 and 1,102,930, respectively. As of December 31, 2015 and 2014, the weighted average grant date fair values per unvested option were $4.82 and $5.19, respectively. The stock-based compensation expense related to unvested RSUs not yet recognized at December 31, 2015, 2014 and 2013 was approximately $2,869, $1,979 and $1,795, respectively, which is expected to be recognized over a weighted average period of 1.69 years, 1.50 years and 1.31 years, respectively. Unvested RSUs as of December 31, 2015 and 2014 were 690,936 and 864,634, respectively. As of December 31, 2015 and 2014, the weighted average grant date fair values per unvested RSU were $6.85 and $4.23, respectively. Employee Stock Purchase Plan In July 2008, we made available an Employee Stock Purchase Plan ("ESPP") in which substantially all of our full-time employees became eligible to participate effective March 18, 2008. Under the plan, employees may contribute through payroll deductions up to 15% of their compensation toward the purchase of our common stock, or $21, whichever is lower. The price per share is equal to the lower of 85% of the fair market price on the first day of the offering period, or 85% of the fair market price on the day of purchase. Proceeds received from the issuance of shares are credited to stockholders' equity in the period that the shares are issued. In 2015, 192,106 shares were purchased in accordance with the ESPP. Net proceeds from the issuance of shares of common stock under the ESPP for the year ended December 31, 2015 were $933. In January 2015, the number of shares available for grant was increased by 267,240, per the ESPP plan documents. At December 31, 2015, 503,285 shares remain available for purchase under the ESPP. For the years ended December 31, 2015, 2014 and 2013, we incurred ESPP expenses of $420, $408 and $211, respectively. Option Acceleration On December 1, 2009, we accelerated the vesting of certain employees' unvested options that were deeply out-of-the-money. The acceleration was done because we believed that there was no longer a compensation incentive tied to performance, given the exercise price of the options that were accelerated. Consistent with ASC 718, we continued to expense the accelerated options over the remaining service period. We do not have a static policy threshold to use for determining whether an option is deeply out-of-the-money. Rather, we believe that the determination should be made in light of current market conditions, probability of stock price recovery within the remaining service period and historical volatility of our stock price. For the purposes of this option acceleration, we determined that options that were out-of-the-money by 30% or more were deeply out-of-the-money. As a result of the option acceleration, approximately 309,000 previously unvested shares became fully vested on December 1, 2009. We incurred an expense of $137 associated with the accelerated options for the year ended December 31, 2013, which has been recorded in the General and administrative line of the consolidated statement of operations. No associated expense has been recorded for the years ended December 31, 2014 and 2015.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2015
Income Taxes
Income Taxes	10. Income Taxes We have deferred income tax assets totaling $55,760 at December 31, 2015, consisting primarily of federal and state net operating loss and credit carryforwards. Due to uncertainty regarding the ultimate realization of these net operating loss and credit carryforwards and other deferred income tax assets, we have established a full valuation allowance (net of deferred tax liabilities for indefinite lived intangibles) on our deferred taxes and will recognize the benefits only as reassessment indicates the benefits are realizable. The determination of the required valuation allowance against net deferred tax assets was made without taking into account the deferred taxes created from the book and tax differences on indefinite-lived assets. All other deferred tax liabilities were properly used as a source of income to support a portion of the deferred tax assets. Our provision for income taxes for 2015 of $468 primarily relates to Alternative Minimum Tax ("AMT") levied on current year taxable income net of allowable AMT net operating loss carryovers, as well as an increase in the deferred tax liability created by the book to tax differences on indefinite-lived assets. We performed an analysis to determine the extent to which we can use our net operating loss carryforwards and other deferred tax assets in future periods, subject to certain limitations imposed by the Internal Revenue Code. We concluded that largely because of our cumulative history of pre-tax losses in years prior to 2015, we cannot predict that the benefits of the net operating loss carryforwards will be realized in future periods, and therefore we continue to provide a full valuation allowance for net deferred tax assets (exclusive of deferred tax liabilities for indefinite-lived intangibles). One significant piece of negative evidence contributing to the full valuation allowance is our cumulative history of pre-tax book losses. At December 31, 2015, we cannot identify sufficient positive evidence to overcome the significant negative evidence. We will perform a similar analysis during 2016 to reassess the ability to realize the net operating loss carryforwards and other deferred tax assets in the future Deferred taxes result from temporary differences between the carrying amounts of assets and liabilities used for financial reporting purposes and the amounts used for income tax purposes. The significant components of our deferred taxes are as follows: December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ $ Research & development and AMT credit carryforwards Stock option grants Allowance for doubtful accounts Deferred revenue Other, net ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets Less valuation allowance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax assets Deferred tax liabilities: Property, plant and equipment ) ) Identified intangible assets ) ) Indefinite-lived intangible assets ) ) Prepaid insurance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax liabilities ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax liability $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Reconciliations between expected income taxes computed at the federal rate of 35% for each of the years ended December 31, 2015, 2014 and 2013, and the provision (benefit) for income taxes is as follows: Years ended December 31, 2015 2014 2013 Income tax provision (benefit) at statutory rate $ $ ) $ ) State income tax, net of federal benefit ) Stock-based compensation Research and development ) ) Other (Decrease) increase in valuation allowance ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provision for (benefit from) income taxes $ $ ) $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The decrease in the valuation allowance in December 31, 2015 is due to current year income. At December 31, 2015, we had federal net operating loss carryforwards of approximately $93,364 to offset future federal taxable income expiring in various years starting in 2018 through 2035. At December 31, 2015, we had state net operating loss carryforwards of $60,491, which expire in various years starting in 2015 through 2035. Additionally, we have credit carryforwards, primarily related to Research and Development, of $5,115, which begin to expire in 2021 through 2035. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences are deductible. The timing and manner in which we can utilize our net operating loss carryforward and future income tax deductions in any year may be limited by provisions of the Internal Revenue Code regarding the change in ownership of corporations. Such limitation may have an impact on the ultimate realization of our carryforwards and future tax deductions. Section 382 of the Internal Revenue Code ("Section 382") imposes limitations on a corporation's ability to utilize net operating losses if it experiences an "ownership change." Section 383 of the Internal Revenue Code imposes similar limitations on other tax attributes such as research and development credits. In general terms, an ownership change may result from transactions increasing the ownership of certain stockholders in the stock of a corporation by more than 50 percentage points over a three-year period. Any unused annual limitation may be carried over to later years, and the amount of the limitation may under certain circumstances be increased by the built-in gains in assets held by us at the time of the change that are recognized in the five-year period after the change. Currently, a portion of our loss carryforwards is limited under Section 382. The components of our provision for (benefit from) income taxes are summarized as follows: Year Ended December 31, 2015 2014 Current: Federal $ $ — State ​ ​ ​ ​ ​ ​ ​ ​ Total provision for income taxes ​ ​ ​ ​ ​ ​ ​ ​ Deferred: Federal ) State ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred provision for (benefit from) income taxes ) ​ ​ ​ ​ ​ ​ ​ ​ Total provision for (benefit from) income taxes $ $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ The U.S. Internal Revenue Service concluded its examination of our U.S. federal tax returns for all years through 2010. Because of net operating losses, our U.S. federal tax returns statutes for those years will remain subject to examination until the losses are utilized. Additionally, state tax return statutes generally remain open due to operating losses. We do not have a tax reserve recorded for tax contingencies. As of December 31, 2015 and 2014, we have not identified any uncertain tax positions and therefore, we have no tax reserve recorded as of December 31, 2015 and 2014.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies
Commitments and Contingencies	11. Commitments and Contingencies Leases We lease our principal administrative and service facilities as well as office equipment under non-cancelable operating leases expiring at various dates through 2021. The terms of the leases are renewable at the end of the lease term. Payments made under operating leases are charged to operations on a straight-line basis over the period of the lease. Differences between straight-line expense and cash payments are recorded as Deferred rent. Rent expense was $3,777, $3,721 and $3,622 for the years ended December 31, 2015, 2014 and 2013, respectively. We have entered into and acquired capital leases with various expiration dates through 2017 which were used to finance equipment, furniture and monitoring devices. Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2015: Operating Leases Capital Leases 2016 $ $ 2017 2018 — 2019 — 2020 — Thereafter — ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Credit Agreement

Credit Agreement	12 Months Ended
	Dec. 31, 2015
Credit Agreement
Credit Agreement	12. Credit Agreement Credit Agreement On December 30, 2014, we entered into a Credit Agreement with Healthcare Financial Solutions, LLC, ("HFS"), previously The General Electric Capital Corporation ("GE Capital"), as agent for the lenders ("Lenders"), and as a Lender and swingline lender. Pursuant to the Credit Agreement, the Lenders agreed to make loans to us as follows; (i) Term Loans in an amount of $25,000 as of the closing date with an uncommitted ability to increase such Term Loans up to an amount not to exceed $10,000 , and (ii) Revolving Loans up to $15,000, which remain undrawn. The loan is recorded on our balance sheet in the amount of $23,194, which is net of a debt issuance discount of $794 related to fees paid to HFS and deferred charges of $74. The HFS Loans bear interest at an annual rate of LIBOR plus 4.0%, subject to a LIBOR floor of 1.0%. The outstanding principal of the Term Loan will be paid as follows: • Beginning April 1, 2015, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $312, plus accrued interest; • Beginning January 1, 2018, the principal amount of the Term Loan will be repaid, on a quarterly basis, in installments of $625, plus accrued interest; • Beginning October 1, 2019, the remaining $16,563 will be paid in full on or before December 30, 2019, or such earlier date upon an acceleration of the Term Loan by the Lenders upon an event of default or termination by us. The Loans are secured by substantially all of our assets and by a pledge of the capital stock of our U.S. based subsidiaries as well as a pledge of 65% of the capital stock of Cardiocore Lab LTD. and BioTelemetry Belgium, BVBA. Covenants The Credit Agreement contains affirmative and financial covenants regarding the operations of our business and certain negative covenants that, among other things, limit our ability to incur additional indebtedness, grant certain liens, make certain investments, merge or consolidate, make certain restricted payments and engage in certain asset dispositions, including a sale of all, or substantially all, of our property. As of December 31, 2015, we were in compliance with our covenants. The Credit Agreement also contains excess payment terms based on the company's financial position. No excess payments will become due in 2016 as a result of our financial position as of December 31, 2015. Debt Extinguishment In February 2014, we entered into a Credit and Security Agreement with The Bancorp Bank for an aggregate amount of $9,830. The proceeds were used to pay off the assumed debt of $8,563 associated with the Mednet acquisition and to fund Mednet's working capital needs. In December 2014, we used the proceeds of the HFS Loans to repay in full the $17,411 outstanding balances of the existing debt. In connection with this repayment, we incurred a debt extinguishment loss of $372, included in Other (loss) income, net in our consolidated statements of operations. This loss includes a pre-payment penalty paid as well as the write-off of the unamortized deferred financing fees related to the existing debt.

Employee Benefit Plan

Employee Benefit Plan	12 Months Ended
	Dec. 31, 2015
Employee Benefit Plan
Employee Benefit Plan	13. Employee Benefit Plan We sponsor a 401(k) Retirement Savings Plan (the Plan) for all eligible employees who meet certain requirements. Participants may contribute, on a pre-tax basis, up to the maximum allowable amount pursuant to Section 401(k) of the Internal Revenue Code. We are not required to contribute to the Plan. In January 2014, we adopted an amendment to the Plan that allowed for an employer matching contribution of 100% of the first 3% of the employees' salary, and 50% of the next 2% of the employees' salary. For the years ended December 31, 2015, 2014 and 2013, we contributed $1,786, $1,483, and $0, respectively. Employer contributions vest immediately.

Segment Information

Segment Information	12 Months Ended
	Dec. 31, 2015
Segment Information
Segment Information	14. Segment Information We operate under three reportable segments: Healthcare, Technology and Research. The Healthcare segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders with our comprehensive suite of cardiac monitoring solutions in a health care setting. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. Our Research segment is engaged in central core laboratory services providing cardiac monitoring, imaging, scientific consulting and data management services for drug and medical device trials. Intercompany revenue relating to the manufacturing of devices by the Technology segment for the other segments is included on the intersegment revenue line. Expenses that can be specifically identified with a segment have been included as deductions in determining pre-tax segment income. Any remaining expenses including research and development costs incurred by the Technology segment for the benefit of the other segments as well as the elimination of costs associated with intercompany revenue are included in Corporate and Other. Also included in Corporate and Other is the Department of Justice settlement, as well as interest expense, net and other financing expenses. We do not allocate assets to the individual segments. Mednet and BMS are primarily included in the Healthcare segment; with the product manufacturing and sales portions being included in the Technology segment. RadCore is included in the Research segment. Healthcare Research Technology Corporate and Other Consolidated 2015 Revenues $ $ $ $ — $ Intersegment revenues — ) — Income (loss) before income taxes ) Depreciation and amortization Capital expenditures — Healthcare Research Technology Corporate and Other Consolidated 2014 Revenues $ $ $ $ — $ Intersegment revenues — — ) — Income (loss) before income taxes ) ) ) Depreciation and amortization Capital expenditures — Healthcare Research Technology Corporate and Other Consolidated 2013 Revenues $ $ $ $ — $ Intersegment revenues — — ) — Income (loss) before income taxes ) ) Depreciation and amortization

Legal Proceedings

Legal Proceedings	12 Months Ended
	Dec. 31, 2015
Legal Proceedings
Legal Proceedings	15. Legal Proceedings From time to time, in the ordinary course of business and like others in the industry, we receive requests for information from government agencies in connection with their regulatory or investigational authority or are involved in traditional employment or business litigation. We review such requests and notices and take appropriate action. The final outcome of any current or future litigation or governmental or internal investigations cannot be accurately predicted, nor can we predict any resulting penalties, fines or other sanctions that may be imposed at the discretion of federal or state regulatory authorities. We record accruals for such contingencies to the extent that it concludes it is probable that a liability has been incurred and the amount of the loss can be estimated. Department of Justice Civil Investigation On August 25, 2011, we received a Civil Investigative Demand issued by the U.S. Department of Justice, Western District of Washington. The CID states that it was issued in the course of an investigation under the Federal False Claims Act and seeks documents for the period January 1, 2007 through the date of the CID. The CID indicates that the investigation concerns allegations that we may have used inappropriate diagnosis codes when submitting claims for payment to Medicare for our real-time, MCOT™ services. During the second quarter of 2014, we reached an agreement in principle for a potential settlement. As a result, we recorded a non-operating charge of $6,400 in the first half of 2014. During the first quarter 2015, the settlement agreement was finalized and we paid $6,400 to the Department of Justice. As part of the settlement, we are not subject to any ongoing obligations or requirements. CardioNet v. Mednet and MedTel Et Al. On May 8, 2012, CardioNet filed suit against Mednet Healthcare Technologies, Inc., MedTel 24, Inc., et al . for patent infringement related to the making, use, offering for sale, and sale of the Heartrak ECAT device and monitoring services. The suit asserted that the defendants are infringing CardioNet's U.S. Patent Nos. 7,212,850, 7,907,996, 6,569,095, 7,587,237 and 7,941,207, which generally cover data collection and reporting. This litigation concluded on January 31, 2014 when the Court entered a Consent Judgment declaring all five CardioNet patents valid and enforceable, and infringed upon by the defendants' making, using, offering to sell, or selling the Heartrak ECAT device and monitoring services. Under the terms of the Consent Judgment entered by the Court, Medtel 24 was granted a limited, non-exclusive, license for the Heartrak ECAT system for a period of one year. On the 364th day of such license, MedTel 24 filed a Motion to Set Aside the Consent Judgment and served us with a Demand for Arbitration. On July 22, 2015, the Court upheld the enforceability of its previously issued Consent Judgment. On October 2, 2015, the Court issued an Order finding MedTel in contempt of the Consent Judgment. MedTel was ordered to return, within 21 days of the Order, all of the Heartrak ECAT materials it improperly retained in violation of the Consent Judgment. The Court further ordered that MedTel's CEO was required to submit a declaration to the Court that all of the materials have been returned within the 21-day window. MedTel delivered the Heartrak ECAT material in compliance with the Order. In a separate Order, the Court ordered MedTel to issue payment for CardioNet's lost profits and expenses totaling $848 as well as attorney fees in the amount of $975. While we intend to vigorously pursue collection, there can be no assurance as to whether MedTel will be able to satisfy the amount covered by the award, and therefore no amount has been recorded. CardioNet v. ScottCare Litigation On May 8, 2012, CardioNet filed suit against The ScottCare Corporation and Ambucor Health Solutions, Inc. in the United States District Court for the Eastern District of Pennsylvania (Civil Action No. 2:12-CV-2516- PBT) for patent infringement under the same five CardioNet patents at issue in the Mednet litigation, related to the making, use, sale, and offering for sale of the ScottCare TeleSentry Mobile Cardiac Telemetry device and monitoring services. CardioNet is seeking an injunction against each defendant, as well as monetary damages. The ScottCare Corporation has asserted counterclaims alleging the patents in suit are invalid and not infringed. The trial court heard argument on motions for summary judgment and motions to limit expert testimony in June 2015, but has not yet issued rulings on these motions. ScottCare has dropped all invalidity challenges with respect to one of the patents in the suit. A trial date has been set for September 12, 2016. Consistent with the accounting for contingent liabilities, no accrual has been recorded in the financial statements. We are vigorously pursuing our claims and defending against the counterclaims. CardioNet v. InfoBionic CardioNet, LLC and Braemar Manufacturing, LLC (collectively, "CardioNet") filed a patent infringement lawsuit against InfoBionic, Inc. on May 8, 2015, in the United States District Court for the District of Massachusetts. CardioNet asserts that InfoBionic's MoMe™ Kardia System infringes CardioNet's U.S. Patent Nos. 6,225,901, 6,940,403, 7,212,850, and 7,907,996, relating to collection and reporting of data. CardioNet seeks an injunction and enhanced damages for willful infringement because InfoBionic had prior knowledge of the asserted patents. In response to CardioNet's infringement assertion, in August 2015, InfoBionic filed petitions at the U.S. Patent and Trademark Office for Inter Partes review ("IPR") of the four asserted patents and filed motions with the District Court to dismiss or stay the lawsuit. The Patent Office has not decided whether it will institute IPR proceedings. The District Court denied InfoBionic's motions and set a claims construction hearing for May 2016 and close of fact discovery for June 2016.

Quarterly Financial Data (Unaud

Quarterly Financial Data (Unaudited)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data (Unaudited)
Quarterly Financial Data (Unaudited)	16. Quarterly Financial Data (Unaudited) The following tables summarize the unaudited quarterly financial data for the last two fiscal years. First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share amount) 2015 Total revenues $ $ $ $ Gross profit Other charges Income from operations Net income (loss) ) Basic net income (loss) per share $ ) $ $ $ Diluted net income (loss) per share $ ) $ $ $ 2014 Total revenues $ $ $ $ Gross profit Other charges (Loss) income from operations ) ) ) Net income (loss) ) ) ) ) Basic net income (loss) per share $ ) $ ) $ ) $ ) Diluted net income (loss) per share $ ) $ ) $ ) $ )

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2015
Subsequent Events
Subsequent Events	17. Subsequent Events We have evaluated subsequent events through February 22, 2016. None have been identified.

Schedule II-Allowance for Doubt

Schedule II-Allowance for Doubtful Accounts	12 Months Ended
	Dec. 31, 2015
Schedule II-Allowance for Doubtful Accounts
Allowance for Doubtful Accounts	SCHEDULE II Beginning Balance Additions Charged To Expense Deductions From Reserve Ending Balance Allowance for Doubtful Accounts Year ended December 31, 2015 $ $ $ ) $ Year ended December 31, 2014 $ $ $ ) $ Year ended December 31, 2013 $ $ $ ) $

Summary of Significant Accoun25

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2015
Summary of Significant Accounting Policies
Principles of Consolidation	Principles of Consolidation The accompanying consolidated financial statements include the accounts of BioTelemetry and its wholly owned subsidiaries. All significant intercompany transactions and balances have been eliminated in consolidation.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires that management make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results may differ from those estimates.
Fair Value of Financial Instruments	Fair Value of Financial Instruments The fair value of financial instruments is defined as the amount at which the instrument could be exchanged in a current transaction between willing parties. Our financial instruments consist primarily of cash and cash equivalents, accounts receivable, other receivables, accounts payable, short-term and long-term debt. With the exception of the long-term debt, the carrying value of these financial instruments approximates their fair value because of their short-term nature (classified as Level 1). For long-term debt, based on the borrowing rates currently available, the fair value was determined to be $24,063 as of December 31, 2015. This is equal to the nominal value, carrying value exclusive of debt discount and deferred charges. We did not have any Level 3 assets or liabilities for the periods ended December 31, 2015 and 2014.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents are held in U.S. financial institutions or in custodial accounts with U.S. financial institutions. Cash equivalents are defined as liquid investments and money market funds with maturity from date of purchase of 90 days or less that are readily convertible into cash and have minimal interest rate risk.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Accounts receivable related to the Healthcare segment are recorded at the time revenue is recognized, net of contractual allowances, and are presented on the balance sheet net of allowance for doubtful accounts. The ultimate collection of accounts receivable may not be known for several months after services have been provided and billed. We record an allowance for doubtful accounts based on the aging of receivables using historical data. The percentages and amounts used to record bad debt expense and the allowance for doubtful accounts are supported by various methods and analyses, including current and historical cash collections, and the aging of receivables by payor. Because of continuing changes in the health care industry and third party reimbursement, it is possible that our estimates of collectability could change, which could have a material impact on our operations and cash flows. Other receivables related to the Technology and Research segments are recorded at the time revenue is recognized, or when products are shipped or services are performed. We estimate allowance for doubtful accounts on a specific account basis, and consider several factors in our analysis including customer specific information and aging of the account. We write off receivables when the likelihood for collection is remote and when we believe collection efforts have been fully exhausted and we do not intend to devote additional resources in attempting to collect. We perform write-offs on a monthly basis. In the Healthcare segment, we wrote off $7,082 and $6,494 of receivables for the years ended December 31, 2015 and 2014, respectively. The impact was a reduction of gross receivables and a reduction in the allowance for doubtful accounts. There were no material write offs in the Technology and Research segments. Additionally, we recorded bad debt expense of $8,047, $9,347 and $7,787 for the years ended December 31, 2015, 2014 and 2013, respectively.
Concentrations of Credit Risk	Concentrations of Credit Risk Financial instruments that potentially subject us to concentrations of credit risk consist primarily of cash, cash equivalents and accounts receivable. We maintain our cash and cash equivalents with high quality financial institutions to mitigate this risk. We perform ongoing credit evaluations of our customers and generally do not require collateral. We record an allowance for doubtful accounts in accordance with the procedures described above. Past-due amounts are written off against the allowance for doubtful accounts when collections are believed to be unlikely and all collection efforts have ceased. At December 31, 2015, 2014 and 2013, one customer, Medicare, accounted for 13% 16%, and 15%, respectively, of our gross accounts receivable.
Inventory	Inventory Inventory is valued at the lower of cost (using first-in, first-out cost method) or market (net realizable value or replacement cost). Management reviews inventory for specific future usage, and estimates of impairment of individual inventory items are recorded to reduce inventory to the lower of cost or market.
Property and Equipment	Property and Equipment Property and equipment is recorded at cost, except for assets acquired in business combinations. Depreciation is recorded over the estimated useful life of each class of depreciable assets, and is computed using the straight-line method. Leasehold improvements are amortized over the shorter of the estimated asset life or term of the lease. Repairs and maintenance costs are charged to expense as incurred.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The carrying value of long-lived assets, other than goodwill and indefinite-lived intangible assets, is evaluated when events or changes in circumstances indicate the carrying value may not be recoverable or the useful life has changed. We consider historical performance and anticipated future results in our evaluation of potential impairment. Accordingly, when indicators of impairment are present, we evaluate the carrying value of these assets in relation to the operating performance of the business and the undiscounted cash flows expected to result from the use of these assets. Impairment losses are recognized when the sum of the expected discounted future cash flows is less than the assets' carrying value.
Equity Method Investments	Equity Method Investments We account for investments using the equity method of accounting if the investment provides us the ability to exercise significant influence, but not control, over the investee. Significant influence is generally deemed to exist if the Company's ownership interest in the voting stock of the investee ranges between 20% and 50%, although other factors, such as representation on the investee's board of directors, are considered in determining whether the equity method of accounting is appropriate. Under the equity method of accounting, the investment is recorded at cost in the consolidated balance sheets under Other assets and adjusted for dividends received and our share of the investee's earnings or losses together with other-than-temporary impairments which are recorded through Interest and other loss, net in the consolidated statements of operations. In December 2015, we acquired approximately 29% of the outstanding stock of Well Bridge Health, Inc. through the conversion of an outstanding note receivable and the related accrued interest. The investment is accounted for under the equity method. As of December 31, 2015, $1,100 was recorded under Other assets. The equity method basis difference of $891 was allocated to equity method goodwill. For the year ended December 31, 2015, no dividends were received and our share of the investee's earnings were not material.
Goodwill and Acquired Intangible Assets	Goodwill and Acquired Intangible Assets Goodwill is the excess of purchase price of an acquired business over the amounts assigned to assets acquired and liabilities assumed in a business combination. In accordance with ASC 350, Intangibles—Goodwill and Other , goodwill is reviewed for impairment annually, or when events arise that could indicate that impairment exists. The provisions of ASC 350 require that we perform a two-step impairment test. In the first step, we compare the fair value of our reporting units to the carrying value of the reporting units. If the carrying value of the net assets assigned to the reporting units exceeds the fair value of the reporting units, then the second step of the impairment test is performed in order to determine the implied fair value of the reporting units' goodwill. If the carrying value of the reporting units' goodwill exceeds the implied fair value, an impairment loss equal to the difference is recorded. For the purpose of performing our goodwill impairment analysis in 2015, we consider our business to be comprised of three reporting units: Healthcare, Technology and Research. We calculate the fair value of the reporting units utilizing a weighting of the income and market approaches. The income approach is based on a discounted cash flow methodology that includes assumptions for, among other things, forecasted income, cash flow, growth rates, income tax rates, expected tax benefits and long-term discount rates, all of which require significant judgment. The market approach utilizes our market data as well as market data from publicly traded companies that are similar to us. There are inherent uncertainties related to these factors and the judgment applied in the analysis. We believe that the combination of an income and a market approach provides a reasonable basis to estimate the fair value of our reporting units. Acquired intangible assets are recorded at fair value on the acquisition date. The estimated fair values and useful lives of intangible assets are determined by assessing many factors including estimates of future operating performance and cash flows of the acquired business, the characteristics of the intangible assets and the experience of the acquired business. Independent appraisal firms may assist with the valuation of acquired assets. The impairment test for indefinite-lived intangibles other than goodwill consists of a comparison of the fair value of the indefinite-lived intangible asset to the carrying value of the asset. We estimate the fair value of the indefinite-lived intangibles using the relief from royalty method.
Revenue Recognition	Revenue Recognition We recognize approximately 82% of our total revenue from patient monitoring services in our Healthcare segment. We receive a significant portion of this revenue from third party commercial payors and governmental entities. We also receive reimbursement directly from patients through co-pay, deductibles and self-pay arrangements. Revenue from the Medicare program is based on reimbursement rates set by CMS. Revenue from contracted commercial payors is recorded at the negotiated contractual rate. Revenue from non-contracted commercial payors is recorded at net realizable value based on historical payment patterns. Adjustments to the estimated net realizable value, based on final settlement with the third party payors, are recorded upon settlement. If we do not have consistent historical information regarding collectability from a given payor, revenue is recognized when cash is received. Unearned amounts are appropriately deferred until service has been completed. For the years ended December 31, 2015, 2014 and 2013, revenue from Medicare as a percentage of total revenue was 34%, 32% and 35%, respectively. Revenue in our Technology segment is received from the sale of products, product repair and supplies which are recognized when shipped, or as service is completed. Research revenue includes revenue for core laboratory services. Our Research revenues are provided on a fee for service basis, and revenue is recognized as the related services are performed. We also provide consulting services on a time and materials basis and recognize revenues as we perform the services. Our site support revenue, consisting of equipment rentals and sales along with related supplies and logistics management, are recognized at the time of sale or over the rental period. Under a typical contract, customers pay us a portion of our fee for these services upon contract execution as an upfront deposit, some of which is typically nonrefundable upon contract termination. Unearned revenues, including upfront deposits, are deferred, and then recognized as the services are performed. For arrangements with multiple deliverables, the revenue is allocated to each element (both delivered and undelivered items) based on their relative selling prices or management's best estimate of their selling prices, when vendor-specific or third-party evidence is unavailable. We record reimbursements received for out-of-pocket expenses, including freight, incurred as revenue in the accompanying consolidated statements of operations. Revenue generally is recognized net of any taxes collected from customers and subsequently remitted to government authorities.
Research and Development Costs	Research and Development Costs Research and development costs are charged to expense as incurred.
Net Income (loss)	Net Income (loss) We compute net income (loss) per share in accordance with ASC 260, Earnings Per Share . The following summarizes the potential outstanding common stock as of the end of each period: December 31, 2015 December 31, 2014 December 31, 2013 Employee stock purchase plan estimated share options outstanding Common stock options and restricted stock units ("RSUs") outstanding Common stock available for grant Common stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Basic net income (loss) per share is computed by dividing net income (loss) by the weighted average number of common shares outstanding during the period. Diluted net income (loss) per share is computed by giving effect to all potential dilutive common shares, including stock options and RSUs. The following table presents the calculation of historical basic and diluted net income (loss) per share: Year Ended December 31, 2015 2014 2013 (in thousands, except per share amounts) Numerator: Net income (loss) $ $ ) $ ) Denominator: Weighted average shares used in computing basic net income (loss) per share Potential dilutive common shares due to dilutive stock option and restricted stock units — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares used in computing diluted net income (loss) per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) per share: Basic net income (loss) per share $ $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income (loss) per share $ $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ If the outstanding vested options or RSUs were exercised or converted into common stock, the result would be anti-dilutive for the years ended December 31, 2014 and 2013. Accordingly, basic and diluted net loss per share are the same for the years ended December 31, 2014 and 2013. Additionally, certain stock options, which are priced higher than the market price of our shares as of December 31, 2015, would be anti-dilutive and therefore have been excluded from the weighted average shares used in computing diluted net income (loss) per share. These options could become dilutive in future periods.
Stock-Based Compensation	Stock-Based Compensation ASC 718, Compensation—Stock Compensation , addresses the accounting for share-based payment transactions in which an enterprise receives employee services in exchange for (a) equity instruments of the enterprise or (b) liabilities that are based on the fair value of the enterprise's equity instruments or that may be settled by the issuance of such equity instruments. ASC 718 requires that an entity measures the cost of equity-based service awards based on the grant-date fair value of the award and recognizes the cost of such awards over the period during which the employee is required to provide service in exchange for the award (the vesting period). ASC 718 requires that an entity measure the cost of liability-based service awards based on current fair value that is re-measured subsequently at each reporting date through the settlement date. The compensation expense associated with performance stock units is recognized over the period between when the performance conditions are deemed probable of achievement and when the awards are vested. We account for equity awards issued to non-employees in accordance with ASC 505-50, Equity-Based Payments to Non-Employees .
Income Taxes	Income Taxes We account for income taxes under the liability method, as described in ASC 740, Income Taxes . Deferred income taxes are recognized for the tax consequences of temporary differences between the tax and financial statement reporting bases of assets and liabilities. A valuation allowance for net deferred tax assets is provided unless realizability is judged to be more likely than not.
Segment Information	Segment Information ASC 280, Segment Reporting , establishes standards for reporting information regarding operating segments in annual financial statements. Operating segments are identified as components of an enterprise for which separate discrete financial information is available for evaluation by the chief operating decision-maker, or decision-making group in making decisions on how to allocate resources and assess performance. We report our business under three segments: Healthcare, Technology and Research. The segments were renamed in the fourth quarter of 2015 to provide a more accurate description of the business conducted by the segment. There is no change to the composition of our reportable segments as a result of the name change. The Healthcare segment is focused on the monitoring of cardiac arrhythmias or heart rhythm disorders in a health care setting. The Technology segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Research segment includes our operations that engage in central core laboratory services in a research environment, which includes certain equipment rental and device sales.
Recent Accounting Pronouncements	Recent Accounting Pronouncements Accounting Pronouncements Recently Adopted In November 2015, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") 2015-17, Income Taxes: Balance Sheet Classification of Deferred Taxes . The standard requires that deferred tax assets and liabilities be classified as noncurrent on the balance sheet. Previously, deferred taxes have been separated into current and noncurrent. We have elected to early adopt this standard at December 31, 2015 and have applied this change in accounting principle retrospectively. As a result of our retrospective adoption, $271 of deferred tax assets have been reclassified from Prepaid and other current assets to Deferred tax liability on our December 31, 2014 Consolidated Balance Sheet. In April 2015, the FASB issued ASU 2015-03, Simplifying the Presentation of Debt Issuance Costs . The standard requires debt issuance costs to be presented on the balance sheet as a direct reduction of the carrying value of the associated debt liability, consistent with the presentation of debt discounts. Previously, debt issuance costs have been presented as a deferred asset. The recognition and measurement requirements will not change as a result of this guidance. We have elected to early adopt this standard at December 31, 2015 and have applied this change in accounting principle retrospectively. As a result of our retrospective adoption, $135 of debt issuance costs have been reclassified from Other assets to Long-term debt on our December 31, 2014 Consolidated Balance Sheet. Accounting Pronouncements Not Yet Adopted In July 2015, the FASB issued ASU 2015-11, Simplifying the Measurement of Inventory . The standard will require inventory to be measured at the lower of cost or net realizable value. The guidance will not apply to inventories for which cost is determined using the last-in, first-out method or the retail inventory method. The standard is effective for annual and interim reporting periods beginning after December 15, 2016. We are currently evaluating the impact the adoption of this standard will have on our consolidated financial statements. In May 2014 and August 2015, the FASB issued ASU 2014-09 and 2015-14, respectively, Revenue from Contracts with Customers , which provides guidance for revenue recognition. The standards will require revenue recognized to represent the transfer of promised goods or services to customers in an amount that reflects the consideration in which a company expects to receive in exchange for those goods or services. The standards also requires new, expanded disclosures regarding revenue recognition. The standards will be effective January 1, 2018 with early adoption permissible beginning January 1, 2017. We are currently evaluating the transition method we will elect and the impact the adoption of this standard will have on our consolidated financial statements.

Summary of Significant Accoun26

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2015
Summary of Significant Accounting Policies
Summary of potential outstanding common stock	December 31, 2015 December 31, 2014 December 31, 2013 Employee stock purchase plan estimated share options outstanding Common stock options and restricted stock units ("RSUs") outstanding Common stock available for grant Common stock ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of calculation of basic and diluted net Income (loss) per share	Year Ended December 31, 2015 2014 2013 (in thousands, except per share amounts) Numerator: Net income (loss) $ $ ) $ ) Denominator: Weighted average shares used in computing basic net income (loss) per share Potential dilutive common shares due to dilutive stock option and restricted stock units — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares used in computing diluted net income (loss) per share ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net income (loss) per share: Basic net income (loss) per share $ $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Diluted net income (loss) per share $ $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Business Combinations (Tables)

Business Combinations (Tables)	12 Months Ended
	Dec. 31, 2015
BMS
Acquisitions
Schedule of purchase price allocation	The purchase price allocation was completed in the first quarter of 2015. The amounts below represent the final fair value of assets acquired. Fair value of assets acquired: Property and equipment $ Goodwill Intangible assets ​ ​ ​ ​ ​ Net assets acquired $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of allocation of finite-lived intangible assets	Estimated Useful Life (Years) Fair Value Customer relationships $ Technology Covenants not to compete ​ ​ ​ ​ ​ ​ ​ ​ Total intangible assets $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Mednet
Acquisitions
Schedule of purchase price allocation	The purchase price allocation was completed in the first quarter of 2015. The amounts below represent the final fair value of assets acquired. Fair value of assets acquired: Cash and cash equivalents $ ) Accounts receivable Inventory Property and equipment Goodwill Intangible assets Other assets ​ ​ ​ ​ ​ Total assets acquired Liabilities assumed: Accounts payable Accrued expenses Other liabilities Long-term debt, capital leases, note payable and related interest ​ ​ ​ ​ ​ Total liabilities assumed ​ ​ ​ ​ ​ Net assets acquired $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of allocation of finite-lived and indefinite-lived intangible assets	Estimated Useful Life (Years) Fair Value Customer relationships $ Technology Covenants not to compete Indefinite-lived trade name ​ ​ ​ ​ ​ ​ ​ ​ Total intangible assets $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of unaudited proforma information representing combined results of operations as if the acquisition had occurred at the beginning of the periods presented	December 31, Unaudited pro forma information 2014 2013 Revenue $ $ ​ ​ ​ ​ ​ ​ ​ ​ Net Loss ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net loss per common share: Basic and Diluted ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average number of shares: Basic ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2015
Inventory
Schedule of inventory	December 31, 2015 2014 Raw materials and supplies $ $ Finished goods ​ ​ ​ ​ ​ ​ ​ ​ Total inventories $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2015
Property and Equipment
Schedule of Property and equipment	December 31, Estimated Useful Life (Years) 2015 2014 Cardiac monitoring devices, device parts and components 3 - 5 $ $ Computers and purchased software 3 - 5 Equipment, tools and molds 3 - 5 Furniture and fixtures 7 Leasehold improvements Life of lease Capital leases 3 - 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total property and equipment, at cost Less accumulated depreciation ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total property and equipment, net $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2015
Goodwill and Intangible Assets
Schedule of changes in the carrying amounts of goodwill by segment	Reporting Segment Healthcare Research Technology Total Balance at December 31, 2014 $ $ $ $ Goodwill acquired during the year — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Balance at December 31, 2015 $ $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of gross carrying amounts and accumulated amortization of the entity's intangible assets	December 31, Estimated Useful Life (Years) 2015 2014 Customer relationships 5 - 15 $ $ Technology including internally developed software 3 - 5 Signed backlog 1 - 4 Unsigned backlog 4 Covenants not to compete 5 - 7 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total intangible assets, gross ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Customer relationships accumulated amortization ) ) Proprietary technology accumulated amortization ) ) Signed backlog accumulated amortization ) ) Unsigned backlog accumulated amortization ) ) Covenants not to compete accumulated amortization ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total accumulated amortization ) ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Indefinite-lived trade names Total intangible assets, net $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Summary of estimated amortization expense for the next five years	The estimated amortization expense for the next five years and thereafter is summarized as follows at December 31, 2015: 2016 $ 2017 2018 2019 2020 Thereafter ​ ​ ​ ​ ​ Total estimated amortization $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2015
Accrued Expenses
Schedule of accrued expenses	December 31, 2015 2014 Accrued compensation $ $ Accrued professional fees Accrued purchases Accrued restructuring costs Other ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Other Charges (Tables)

Other Charges (Tables)	12 Months Ended
	Dec. 31, 2015
Other Charges
Summary of expenses related to other charges	Year ended December 31, 2015 2014 2013 Legal fees $ $ $ Severance and employee related costs Professional fees Expenses related to facility closure — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Total $ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2015
Stockholders' Equity
Summary of stock option under all equity incentive plans	Number of Shares Weighted Average Exercise Price Options outstanding as of December 31, 2012 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Cancelled ) $ Exercised ) $ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding as of December 31, 2013 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Cancelled ) $ Exercised ) $ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding as of December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Cancelled ) $ Exercised ) $ ​ ​ ​ ​ ​ ​ ​ ​ Options outstanding as of December 31, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Summary of total outstanding stock options	A summary of total outstanding stock options as of December 31, 2015 is as follows: Options Outstanding Options Exercisable Range of Exercise Price Number Outstanding Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price Number Exercisable Weighted Average Remaining Contractual Life (in years) Weighted Average Exercise Price $0.70 - $7.50 $ $ $7.51 - $15.00 $ $ $15.01 - $22.50 $ $ $22.51 - $31.18 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ $0.70 - $31.18 $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Summary of certain additional information with respect to options	(In thousands) 2015 2014 2013 Aggregate intrinsic value of options outstanding at year-end $ $ $ Aggregate intrinsic value of options exercisable at year-end Aggregate intrinsic value of options exercised during the year
Summary of Restricted stock units activity	Number of Shares Weighted Average Grant Date Fair Value Restricted stock outstanding as of December 31, 2012 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited ) $ Vested ) $ ​ ​ ​ ​ ​ ​ ​ ​ Restricted stock outstanding as of December 31, 2013 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited ) $ Vested ) $ ​ ​ ​ ​ ​ ​ ​ ​ Restricted stock outstanding as of December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited ) $ Vested ) $ ​ ​ ​ ​ ​ ​ ​ ​ Restricted stock outstanding as of December 31, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Summary of total outstanding RSUs	In addition, a summary of total outstanding RSUs as of December 31, 2015 is as follows: Range of Grant Price RSUs Outstanding $2.16 - $6.75 $6.76 - $9.75 ​ ​ ​ ​ ​ $2.16 - $9.75 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Summary of Performance stock units activity	Number of Shares Weighted Average Grant Date Fair Value Performance stock outstanding as of December 31, 2013 — — ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted $ Forfeited — — Vested — — ​ ​ ​ ​ ​ ​ ​ ​ Performance stock outstanding as of December 31, 2014 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Granted — — Forfeited ) $ Vested — — ​ ​ ​ ​ ​ ​ ​ ​ Performance stock outstanding as of December 31, 2015 $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of weighted average assumptions used to estimate the fair value of the stock-based awards	Year Ended December 31, 2015 2014 2013 Expected volatility % % % Expected term (in years) Weighted average risk-free interest rate % % % Expected dividends % % % Weighted average grant date fair value per option $ $ $ Weighted average grant date fair value per RSU $ $ $

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2015
Income Taxes
Schedule of the components of the entity's deferred tax assets and liabilities	December 31, 2015 2014 Deferred tax assets: Net operating loss carryforwards $ $ Research & development and AMT credit carryforwards Stock option grants Allowance for doubtful accounts Deferred revenue Other, net ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax assets Less valuation allowance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax assets Deferred tax liabilities: Property, plant and equipment ) ) Identified intangible assets ) ) Indefinite-lived intangible assets ) ) Prepaid insurance ) ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred tax liabilities ) ) ​ ​ ​ ​ ​ ​ ​ ​ Net deferred tax liability $ ) $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of reconciliations between expected income taxes computed at the federal rate and the provision (benefit) for income taxes	Years ended December 31, 2015 2014 2013 Income tax provision (benefit) at statutory rate $ $ ) $ ) State income tax, net of federal benefit ) Stock-based compensation Research and development ) ) Other (Decrease) increase in valuation allowance ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Provision for (benefit from) income taxes $ $ ) $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​
Schedule of the components of the entity's provision for (benefit from) income taxes	Year Ended December 31, 2015 2014 Current: Federal $ $ — State ​ ​ ​ ​ ​ ​ ​ ​ Total provision for income taxes ​ ​ ​ ​ ​ ​ ​ ​ Deferred: Federal ) State ) ​ ​ ​ ​ ​ ​ ​ ​ Total deferred provision for (benefit from) income taxes ) ​ ​ ​ ​ ​ ​ ​ ​ Total provision for (benefit from) income taxes $ $ ) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2015
Commitments and Contingencies
Summary of the future minimum lease payments under non-cancelable operating and capital leases	Future minimum lease payments under non-cancelable operating and capital leases are summarized as follows at December 31, 2015: Operating Leases Capital Leases 2016 $ $ 2017 2018 — 2019 — 2020 — Thereafter — ​ ​ ​ ​ ​ ​ ​ ​ $ $ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​

Segment Information (Tables)

Segment Information (Tables)	12 Months Ended
	Dec. 31, 2015
Segment Information
Summary of financial information concerning the entity's reportable segments	Healthcare Research Technology Corporate and Other Consolidated 2015 Revenues $ $ $ $ — $ Intersegment revenues — ) — Income (loss) before income taxes ) Depreciation and amortization Capital expenditures — Healthcare Research Technology Corporate and Other Consolidated 2014 Revenues $ $ $ $ — $ Intersegment revenues — — ) — Income (loss) before income taxes ) ) ) Depreciation and amortization Capital expenditures — Healthcare Research Technology Corporate and Other Consolidated 2013 Revenues $ $ $ $ — $ Intersegment revenues — — ) — Income (loss) before income taxes ) ) Depreciation and amortization

Quarterly Financial Data (Una37

Quarterly Financial Data (Unaudited) (Tables)	12 Months Ended
	Dec. 31, 2015
Quarterly Financial Data (Unaudited)
Summary of the unaudited quarterly financial data	First Quarter Second Quarter Third Quarter Fourth Quarter (in thousands, except per share amount) 2015 Total revenues $ $ $ $ Gross profit Other charges Income from operations Net income (loss) ) Basic net income (loss) per share $ ) $ $ $ Diluted net income (loss) per share $ ) $ $ $ 2014 Total revenues $ $ $ $ Gross profit Other charges (Loss) income from operations ) ) ) Net income (loss) ) ) ) ) Basic net income (loss) per share $ ) $ ) $ ) $ ) Diluted net income (loss) per share $ ) $ ) $ ) $ )

Organization and Description 38

Organization and Description of Business (Details)	12 Months Ended
	Dec. 31, 2015segment
Organization and Description of Business
Number of operating segments	3

Summary of Significant Accoun39

Summary of Significant Accounting Policies - A/R and Allowance for Doubtful (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Accounts receivable and allowance for doubtful accounts
Fair value of long-term debt	$ 24,063
Bad debt expense	8,047	$ 9,347	$ 7,787
Healthcare
Accounts receivable and allowance for doubtful accounts
Write-off of receivables	$ 7,082	$ 6,494

Summary of Significant Accoun40

Summary of Significant Accounting Policies - Concentrations of Credit Risk (Details) - Gross accounts receivable - Credit concentration risk - customer	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Concentrations of credit risk
Number of major customers	1
Medicare
Concentrations of credit risk
Concentration risk (as a percent)	13.00%	16.00%	15.00%

Summary of Significant Accoun41

Summary of Significant Accounting Policies - Equity Method Investments (Details) - Well Bridge Health, Inc $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Equity Method Investments
Percentage of ownership acquired	29.00%
Dividends from equity investment	$ 0
Goodwill
Equity Method Investments
Equity method investment	891
Other Assets
Equity Method Investments
Equity method investment	$ 1,100

Summary of Significant Accoun42

Summary of Significant Accounting Policies - Goodwill and Acquired Intangible assets (Details) - segment	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill and Acquired Intangible Assets
Number of reporting units	3
Revenue | Service concentration | Patient monitoring services | Healthcare
Revenue Recognition
Concentration risk (as a percent)	82.00%
Revenue | Payor concentration | Medicare
Revenue Recognition
Concentration risk (as a percent)	34.00%	32.00%	35.00%

Summary of Significant Accoun43

Summary of Significant Accounting Policies - Net loss & Stock-based Compensation (Details) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)$ / sharesshares	Sep. 30, 2015USD ($)$ / shares	Jun. 30, 2015USD ($)$ / shares	Mar. 31, 2015USD ($)$ / shares	Dec. 31, 2014USD ($)$ / sharesshares	Sep. 30, 2014USD ($)$ / shares	Jun. 30, 2014USD ($)$ / shares	Mar. 31, 2014USD ($)$ / shares	Dec. 31, 2015USD ($)segment$ / sharesshares	Dec. 31, 2014USD ($)$ / sharesshares	Dec. 31, 2013USD ($)$ / sharesshares
Summary of Significant Accounting Policies
Employee stock purchase plan estimated share options outstanding (in shares)	43,446				39,232				43,446	39,232	81,848
Common stock options and restricted stock units ("RSUs") outstanding (in shares)	4,111,455				4,115,486				4,111,455	4,115,486	3,993,590
Common stock available for grant (in shares)	2,553,673				2,262,168				2,553,673	2,262,168	1,761,840
Common stock (in shares)	27,277,939				26,693,248				27,277,939	26,693,248	25,812,754
Total (in shares)	33,986,513				33,110,134				33,986,513	33,110,134	31,650,032
Numerator:
Net income (loss) | $	$ 2,848	$ 2,478	$ 2,171	$ (69)	$ (1,654)	$ (29)	$ (3,988)	$ (4,122)	$ 7,428	$ (9,793)	$ (7,319)
Denominator:
Weighted average shares used in computing basic net income (loss) per share									27,116,300	26,444,626	25,543,646
Potential dilutive common shares due to dilutive stock option and restricted stock units									1,972,911
Weighted average shares used in computing diluted net loss per share									29,089,211	26,444,626	25,543,646
Net income (loss) per common share:
Basic net income (loss) per share | $ / shares	$ 0.10	$ 0.09	$ 0.08	$ 0	$ (0.06)	$ 0	$ (0.15)	$ (0.16)	$ 0.27	$ (0.37)	$ (0.29)
Diluted net income (loss) per share | $ / shares	$ 0.10	$ 0.08	$ 0.08	$ 0	$ (0.06)	$ 0	$ (0.15)	$ (0.16)	$ 0.26	$ (0.37)	$ (0.29)
Segment Information
Number of reportable segments | segment									3

Summary of Significant Accoun44

Summary of Significant Accounting Policies - Recent Accounting Pronouncements (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Nov. 30, 2015	Apr. 30, 2015	Dec. 31, 2014
Recent Accounting Pronouncements
Prepaid expenses and other current assets	$ 1,505			$ 2,081
Deferred tax liability	1,233			987
Other assets	1,732			1,153
Long-term debt	$ 21,944			$ 22,935
Accounting Standards Update ("ASU") 2015-17 - Income Taxes: Balance Sheet Classification of Deferred Taxes | Retrospective early adoption
Recent Accounting Pronouncements
Prepaid expenses and other current assets		$ (271)
Deferred tax liability		$ 271
Accounting Standards Update ("ASU") 2015-03 - Simplifying the Presentation of Debt Issuance Costs | Retrospective early adoption
Recent Accounting Pronouncements
Other assets			$ (135)
Long-term debt			$ 135

Business Combinations - RadCore

Business Combinations - RadCore Lab (Details) - RadCore - Cardiocore $ in Thousands	Jun. 03, 2014USD ($)shares
Acquisitions
Purchase consideration in cash	$ 400
Number of shares of common stock issued for acquisition | shares	22,513
Value of common stock issued for acquisition	$ 200

Business Combinations - Biomedi

Business Combinations - Biomedical Systems Corporation (Details) - USD ($) $ in Thousands	Apr. 03, 2014	Mar. 31, 2015	Dec. 31, 2015	Dec. 31, 2014
Fair value of assets acquired:
Goodwill			$ 29,831	$ 29,596
BMS | CardioNet, LLC
Acquisitions
Purchase consideration in cash	$ 8,000
Number of shares of common stock issued for acquisition	62,859
Value of common stock issued for acquisition	$ 650
Fair value of assets acquired:
Property and equipment		$ 882
Goodwill		3,559
Intangible assets		4,209
Net assets acquired		8,650
BMS | CardioNet, LLC | Customer relationships
Fair value of assets acquired:
Intangible assets		$ 2,100
Estimated Useful Life		15 years
BMS | CardioNet, LLC | Technology
Fair value of assets acquired:
Intangible assets		$ 1,849
Estimated Useful Life		4 years
BMS | CardioNet, LLC | Covenants not to compete
Fair value of assets acquired:
Intangible assets		$ 260
Estimated Useful Life		7 years

Business Combinations - Mednet

Business Combinations - Mednet Healthcare Technologies(Details) - USD ($) $ / shares in Units, $ in Thousands	Jan. 31, 2014	Mar. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2015
Fair value of assets acquired:
Goodwill			$ 29,596		$ 29,831
Mednet
Liabilities assumed:
Long-term debt, capital leases, note payable and related interest	$ 9,720
Pro-Forma Information
Revenue from acquisition			23,355
Revenue			170,076	$ 155,415
Net Loss			$ (8,014)	$ (8,604)
Net loss per common share: Basic and Diluted (in dollars per share)			$ (0.30)	$ (0.34)
Weighted average number of shares: Basic			26,444,626	25,640,295
Mednet | CardioNet, LLC
Acquisitions
Purchase consideration in cash	$ 5,500
Number of shares of common stock issued for acquisition	128,866
Value of common stock issued for acquisition	$ 940
Fair value of assets acquired:
Cash and cash equivalents		$ (199)
Accounts receivable		3,879
Inventory		311
Property and equipment		3,429
Goodwill		9,589
Intangible assets		9,220
Other assets		317
Total assets acquired		26,546
Liabilities assumed:
Accounts payable		4,427
Accrued expenses		2,932
Other liabilities		3,027
Long-term debt, capital leases, note payable and related interest		9,720
Total liabilities assumed		20,106
Net assets acquired		6,440
Mednet | CardioNet, LLC | Indefinite-lived trade name
Fair value of assets acquired:
Intangible assets		700
Mednet | CardioNet, LLC | Customer relationships
Fair value of assets acquired:
Intangible assets		$ 6,500
Estimated Useful Life		13 years
Mednet | CardioNet, LLC | Technology
Fair value of assets acquired:
Intangible assets		$ 1,600
Estimated Useful Life		5 years
Mednet | CardioNet, LLC | Covenants not to compete
Fair value of assets acquired:
Intangible assets		$ 420
Estimated Useful Life		5 years

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Inventory
Raw materials and supplies	$ 2,115	$ 2,347
Finished goods	263	219
Total inventories	$ 2,378	$ 2,566

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property and equipment
Total property and equipment, at cost	$ 80,133	$ 71,557
Less accumulated depreciation	(54,579)	(49,854)
Total property and equipment, net	25,554	21,703
Depreciation expense	8,987	8,858	$ 9,978
Cardiac monitoring devices, device parts and components
Property and equipment
Total property and equipment, at cost	$ 52,087	47,190
Cardiac monitoring devices, device parts and components | Minimum
Property and equipment
Estimated Useful Life	3 years
Cardiac monitoring devices, device parts and components | Maximum
Property and equipment
Estimated Useful Life	5 years
Computers and purchased software
Property and equipment
Total property and equipment, at cost	$ 15,392	12,614
Computers and purchased software | Minimum
Property and equipment
Estimated Useful Life	3 years
Computers and purchased software | Maximum
Property and equipment
Estimated Useful Life	5 years
Equipment, tools and molds
Property and equipment
Total property and equipment, at cost	$ 5,858	5,543
Equipment, tools and molds | Minimum
Property and equipment
Estimated Useful Life	3 years
Equipment, tools and molds | Maximum
Property and equipment
Estimated Useful Life	5 years
Furniture and fixtures
Property and equipment
Estimated Useful Life	7 years
Total property and equipment, at cost	$ 1,863	1,396
Leasehold improvements
Property and equipment
Total property and equipment, at cost	3,049	2,930
Capital leases
Property and equipment
Total property and equipment, at cost	$ 1,884	$ 1,884
Capital leases | Minimum
Property and equipment
Estimated Useful Life	3 years
Capital leases | Maximum
Property and equipment
Estimated Useful Life	7 years

Goodwill and Intangible Asset50

Goodwill and Intangible Assets - Changes In Carrying Amounts (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	$ 29,596
Goodwill acquired during the year	235
Balance at the end of the period	29,831
Healthcare
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	14,489
Goodwill acquired during the year	235
Balance at the end of the period	14,724
Research
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	11,950
Balance at the end of the period	11,950
Technology
Changes in the carrying amounts of goodwill by segment
Balance at the beginning of the period	3,157
Balance at the end of the period	$ 3,157

Goodwill and Intangible Asset51

Goodwill and Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Intangible assets
Total intangible assets, gross	$ 29,022	$ 28,260
Total accumulated amortization	(11,541)	(8,040)
Total intangible assets, net	19,981	22,720
Estimated amortization expenses
2,016	3,402
2,017	3,002
2,018	2,517
2,019	2,030
2,020	1,996
Thereafter	4,534
Total estimated amortization	17,481
Amortization expense	3,501	3,692	$ 2,340
Impairment of Goodwill and indefinite lived intangibles	0	0	$ 0
Indefinite-lived trade name
Intangible assets
Indefinite-lived trade names	2,500	2,500
Customer relationships
Intangible assets
Total intangible assets, gross	10,700	10,700
Total accumulated amortization	$ (2,520)	(1,556)
Customer relationships | Minimum
Intangible assets
Estimated Useful Life	5 years
Customer relationships | Maximum
Intangible assets
Estimated Useful Life	15 years
Technology including internally developed software
Intangible assets
Total intangible assets, gross	$ 13,522	12,760
Total accumulated amortization	$ (5,422)	(3,855)
Technology including internally developed software | Minimum
Intangible assets
Estimated Useful Life	3 years
Technology including internally developed software | Maximum
Intangible assets
Estimated Useful Life	5 years
Signed backlog
Intangible assets
Total intangible assets, gross	$ 3,160	3,160
Total accumulated amortization	$ (2,609)	(1,984)
Signed backlog | Minimum
Intangible assets
Estimated Useful Life	1 year
Signed backlog | Maximum
Intangible assets
Estimated Useful Life	4 years
Unsigned backlog
Intangible assets
Estimated Useful Life	4 years
Total intangible assets, gross	$ 600	600
Total accumulated amortization	(500)	(350)
Covenants not to compete
Intangible assets
Total intangible assets, gross	1,040	1,040
Total accumulated amortization	$ (490)	$ (295)
Covenants not to compete | Minimum
Intangible assets
Estimated Useful Life	5 years
Covenants not to compete | Maximum
Intangible assets
Estimated Useful Life	7 years

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Accrued Expenses
Accrued compensation	$ 6,454	$ 5,296
Accrued professional fees	1,858	8,289
Accrued purchases	110	977
Accrued restructuring costs	62	689
Other	2,746	3,209
Total	$ 11,230	$ 18,460

Other Charges (Details)

Other Charges (Details) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Other Charges
Legal fees									$ 5,764	$ 4,691	$ 5,516
Professional fees									50	669	492
Severance and employee related costs									249	1,738	1,410
Expenses related to facility closure											564
Total	$ 1,601	$ 1,392	$ 1,210	$ 1,860	$ 2,073	$ 1,045	$ 1,000	$ 2,980	$ 6,063	$ 7,098	$ 7,982

Shareholders' Equity (Details)

Shareholders' Equity (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stockholders' Equity
Common stock, shares authorized	200,000,000	200,000,000	200,000,000
Common stock, shares outstanding	27,277,939	26,693,248	25,812,754
Preferred stock, shares authorized	0	0
Preferred stock, shares outstanding	0	0
Stock-based compensation
Common stock available for grant (in shares)	2,553,673	2,262,168	1,761,840
2008 Option Plan
Stock-based compensation
Common stock available for grant (in shares)	2,050,388
Stock options
Number of Shares
Balance at the beginning of the period (in shares)	3,250,852	3,135,934	2,905,761
Granted (in shares)	427,786	582,012	729,439
Cancelled (in shares)	(181,777)	(310,303)	(393,770)
Exercised (in shares)	(76,342)	(156,791)	(105,496)
Balance at the end of the period (in shares)	3,420,519	3,250,852	3,135,934
Weighted Average Exercise Price
Balance at the beginning of the period (in dollars per share)	$ 6.40	$ 5.83	$ 6.44
Granted (in dollars per share)	10.39	8.45	3.24
Cancelled (in dollars per share)	11.32	6.55	5.93
Exercised (in dollars per share)	3.82	3.37	4.43
Balance at the end of the period (in dollars per share)	$ 6.69	$ 6.40	$ 5.83
Stock options | 2008 Option Plan
Stock-based compensation
Increase in the number of options available to be granted as a percentage of total number of common shares outstanding	4.00%
Increase in the number of options available to be granted (in shares)	1,500,000
Stock options | 2008 Option Plan | Maximum
Stock-based compensation
Expiration period	10 years

Shareholders' Equity - Outstand

Shareholders' Equity - Outstanding Stock Option (Details)	12 Months Ended
	Dec. 31, 2015$ / sharesshares
$0.70 - $7.50
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	$ 0.70
Range of exercise prices, high end of range (in dollars per share)	$ 7.50
Options Outstanding
Number Outstanding (in shares) | shares	2,325,971
Weighted - Average Remaining Contractual Life	5 years 9 months 18 days
Weighted - Average Exercise Price (in dollars per share)	$ 4.09
Options Exercisable
Number Exercisable (in shares) | shares	2,056,224
Weighted - Average Remaining Contractual Life	5 years 7 months 10 days
Weighted - Average Exercise Price (in dollars per share)	$ 4.15
$7.51 - $15.00
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	7.51
Range of exercise prices, high end of range (in dollars per share)	$ 15
Options Outstanding
Number Outstanding (in shares) | shares	845,824
Weighted - Average Remaining Contractual Life	8 years 6 months 18 days
Weighted - Average Exercise Price (in dollars per share)	$ 9.62
Options Exercisable
Number Exercisable (in shares) | shares	277,656
Weighted - Average Remaining Contractual Life	7 years 11 months 27 days
Weighted - Average Exercise Price (in dollars per share)	$ 9.34
$15.01 - $22.50
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	15.01
Range of exercise prices, high end of range (in dollars per share)	$ 22.50
Options Outstanding
Number Outstanding (in shares) | shares	190,824
Weighted - Average Remaining Contractual Life	3 years 3 months 15 days
Weighted - Average Exercise Price (in dollars per share)	$ 18.38
Options Exercisable
Number Exercisable (in shares) | shares	190,824
Weighted - Average Remaining Contractual Life	3 years 3 months 15 days
Weighted - Average Exercise Price (in dollars per share)	$ 18.38
$22.51 - $31.18
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	22.51
Range of exercise prices, high end of range (in dollars per share)	$ 31.18
Options Outstanding
Number Outstanding (in shares) | shares	57,900
Weighted - Average Remaining Contractual Life	2 years 7 months 10 days
Weighted - Average Exercise Price (in dollars per share)	$ 29.83
Options Exercisable
Number Exercisable (in shares) | shares	57,900
Weighted - Average Remaining Contractual Life	2 years 7 months 10 days
Weighted - Average Exercise Price (in dollars per share)	$ 29.83
$0.70 - $31.18
Summary of total outstanding stock options
Range of exercise prices, low end of range (in dollars per share)	0.70
Range of exercise prices, high end of range (in dollars per share)	$ 31.18
Options Outstanding
Number Outstanding (in shares) | shares	3,420,519
Weighted - Average Remaining Contractual Life	6 years 3 months 15 days
Weighted - Average Exercise Price (in dollars per share)	$ 6.69
Options Exercisable
Number Exercisable (in shares) | shares	2,582,604
Weighted - Average Remaining Contractual Life	5 years 7 months 17 days
Weighted - Average Exercise Price (in dollars per share)	$ 6.34

Shareholders' Equity - Aggregat

Shareholders' Equity - Aggregate Intrinsic Value of Options (Details) - Stock options - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock-based compensation
Aggregate intrinsic value of options outstanding at year-end	$ 19,436	$ 15,258	$ 11,183
Aggregate intrinsic value of options exercisable at year-end	16,124	9,918	4,382
Aggregate intrinsic value of options exercised during the year	662	840	422
Total cash received from the exercise of stock options	$ 291	$ 529	$ 467

Shareholders' Equity - PSU (Det

Shareholders' Equity - PSU (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
RSUs
Number of Shares
Balance at the beginning of the period (in shares)	864,634	857,656	763,342
Granted (in shares)	328,060	292,079	457,200
Forfeited (in shares)	(50,642)	(89,664)	(82,813)
Vested (in shares)	(451,116)	(195,437)	(280,073)
Balance at the end of the period (in shares)	690,936	864,634	857,656
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per shares)	$ 4.23	$ 3.15	$ 3.54
Granted (in dollars per share)	9.70	8.48	3.52
Forfeited (in dollars per share)	6.90	3.30	3.07
Vested (in dollars per share)	3.89	6.27	4.82
Balance at the end of the period (in dollars per shares)	$ 6.85	$ 4.23	$ 3.15
PSUs
Number of Shares
Balance at the beginning of the period (in shares)	284,423
Granted (in shares)		284,423
Forfeited (in shares)	(18,433)
Balance at the end of the period (in shares)	265,990	284,423
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per shares)	$ 8.68
Granted (in dollars per share)		$ 8.68
Forfeited (in dollars per share)	$ 8.68
Balance at the end of the period (in dollars per shares)		$ 8.68

Shareholders' Equity - Outsta58

Shareholders' Equity - Outstanding RSUs (Details) - RSUs - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Stock-based compensation
RSUs Outstanding (in shares)	690,936	864,634	857,656	763,342
$2.16 - $6.75
Stock-based compensation
RSUs Outstanding (in shares)	255,564
$2.16 - $6.75 | Minimum
Stock-based compensation
Grant price (in dollars per share)	$ 2.16
$2.16 - $6.75 | Maximum
Stock-based compensation
Grant price (in dollars per share)	$ 6.75
$6.76 - $9.75
Stock-based compensation
RSUs Outstanding (in shares)	435,372
$6.76 - $9.75 | Minimum
Stock-based compensation
Grant price (in dollars per share)	$ 6.76
$6.76 - $9.75 | Maximum
Stock-based compensation
Grant price (in dollars per share)	$ 9.75
$2.16 - $9.75
Stock-based compensation
RSUs Outstanding (in shares)	690,936
$2.16 - $9.75 | Minimum
Stock-based compensation
Grant price (in dollars per share)	$ 2.16
$2.16 - $9.75 | Maximum
Stock-based compensation
Grant price (in dollars per share)	$ 9.75

Shareholders' Equity - PSUs & P

Shareholders' Equity - PSUs & PSOs (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
PSUs
Number of Shares
Balance at the beginning of the period (in shares)	265,990	284,423
Granted (in shares)			284,423
Forfeited (in shares)		(18,433)
Balance at the end of the period (in shares)		265,990	284,423
Weighted Average Grant Date Fair Value
Balance at the beginning of the period (in dollars per shares)		$ 8.68
Granted (in dollars per share)			$ 8.68
Forfeited (in dollars per share)		$ 8.68
Balance at the end of the period (in dollars per shares)			$ 8.68
Number of Shares
Stock based compensation		$ 711	$ 0
PSOs
Number of Shares
Granted (in shares)		200,000
Forfeited ( in shares )		0
Vested (in shares)		0
Stock based compensation		$ 0
Scenario Forecast | PSUs
Number of Shares
Stock based compensation	$ 444

Shareholders' Equity - Stock Op

Shareholders' Equity - Stock Option (Details) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Weighted average assumptions used to estimate the fair value of the stock-based awards
Expected volatility (as a percent)	66.50%	62.80%	60.30%
Expected term	6 years 8 months 19 days	6 years 5 months 27 days	6 years 8 months 16 days
Weighted-average risk-free interest rate (as a percent)	1.68%	1.85%	1.34%
Expected dividends (as a percent)	0.00%	0.00%	0.00%
Weighted average grant date fair value per option (in dollars per share)	$ 6.58	$ 5	$ 1.90
Weighted average grant fair value per RSU (in dollars per share)	$ 9.71	$ 8.43	$ 3.52
Stock options
Weighted average assumptions used to estimate the fair value of the stock-based awards
Future forfeiture rate (as a percent)	9.20%
RSUs
Weighted average assumptions used to estimate the fair value of the stock-based awards
Future forfeiture rate (as a percent)	6.70%
PSUs
Weighted average assumptions used to estimate the fair value of the stock-based awards
Future forfeiture rate (as a percent)	0.00%

Shareholders' Equity - Stock 61

Shareholders' Equity - Stock Option and RSU (Details) - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock options
Stock-based compensation
Total compensation cost of options granted but not yet vested	$ 3,608	$ 2,744	$ 2,644
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	2 years 7 months 28 days	2 years 8 months 5 days	2 years 1 month 21 days
Unvested awards (in shares)	837,915	1,102,930
Weighted-average grant-date fair value of unvested awards (in dollars per share)	$ 4.82	$ 5.19
RSUs
Stock-based compensation
Stock-based compensation expense related to nonvested awards	$ 2,869	$ 1,979	$ 1,795
Weighted average remaining periods over which unrecognized amounts are expected to be recognized	1 year 8 months 9 days	1 year 6 months	1 year 3 months 22 days
Unvested awards (in shares)	690,936	864,634
Weighted-average grant-date fair value of unvested awards (in dollars per share)	$ 6.85	$ 4.23

Shareholders' Equity - Employee

Shareholders' Equity - Employee Stock Purchase Plan (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	Jan. 31, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Stock-based compensation
Remaining shares available under Plan		2,553,673	2,262,168	1,761,840
Employee Stock Purchase Plan
Stock-based compensation
Maximum percentage of compensation that employees may contribute through payroll deductions		15.00%
Maximum amount that employees may contribute through payroll deductions		$ 21
Percentage of the fair market price on the first day of the offering period or the market price as on the day of purchase		85.00%
Common stock purchased (in shares)		192,106
Proceeds from the issuance of shares of common stock (in dollars)		$ 933
Increase in number of shares available for grant	267,240
Remaining shares available under Plan		503,285
Expenses incurred		$ 420	$ 408	$ 211

Shareholders' Equity - Option A

Shareholders' Equity - Option Acceleration (Details) - Stock options - USD ($) $ in Thousands	Dec. 01, 2009	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Option Acceleration
Threshold percentage for determining deeply out-of-the-money options	30.00%
Number of previously unvested shares, which became fully vested as a result of option acceleration	309,000
Expense associated with the accelerated options		$ 0	$ 0	$ 137

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Deferred tax assets:
Net operating loss carryforwards	$ 36,149	$ 38,540
Research & development and AMT credit carryforwards	5,115	5,314
Stock option grants	7,483	7,410
Allowance for doubtful accounts	4,473	4,532
Deferred revenue	964	947
Other, net	1,576	571
Total deferred tax assets	55,760	57,314
Less valuation allowance	(49,759)	(52,998)
Net deferred tax assets	6,001	4,316
Deferred tax liabilities:
Property, plant and equipment	(3,027)	(360)
Identified intangible assets	(2,798)	(3,756)
Indefinite lived intangible assets	(1,233)	(987)
Prepaid insurance	(176)	(200)
Total deferred tax liabilities	(7,234)	(5,303)
Net deferred tax liability	$ (1,233)	$ (987)
Reconciliation between expected income taxes computed at the federal rate and the provision (benefit) for income taxes
Federal rate of income tax (as a percent)	35.00%	35.00%	35.00%
Income tax provision (benefit) at statutory rate	$ 2,763	$ (4,237)	$ (2,486)
State income tax, net of federal benefit	(239)	4	716
Stock-based compensation	133	43	203
Research and development	634	(626)	(488)
Other	416	368	670
(Decrease) increase in valuation allowance	(3,239)	2,135	1,600
Total provision for (benefit from) income taxes	$ 468	(2,313)	215
Net Operating Loss Carryforwards
Minimum percentage of increase in ownership of stockholders for ownership change	50.00%
Period over which a minimum 50 percent of increase in ownership is required for ownership change	3 years
Period of recognition of built-in gains in assets held at the time of ownership change	5 years
Current:
Federal	$ 173
State	50	186
Total provision for income taxes	223	186
Deferred:
Federal	220	(2,355)
State	25	(144)
Total deferred provision for (benefit from) income taxes	245	(2,499)	53
Total provision for (benefit from) income taxes	468	(2,313)	$ 215
Tax reserve recorded for tax contingencies	0	$ 0
Federal
Net Operating Loss Carryforwards
Net operating loss carryforwards	93,364
State
Net Operating Loss Carryforwards
Net operating loss carryforwards	60,491
Research and Development
Net Operating Loss Carryforwards
Tax credit carryforward	$ 5,115

Commitments and Contingencies65

Commitments and Contingencies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies
Rent expense	$ 3,777	$ 3,721	$ 3,622
Future minimum lease payments under non-cancelable operating leases
2,016	3,429
2,017	3,314
2,018	3,260
2,019	1,838
2,020	1,533
Thereafter	318
Total	13,692
Future minimum lease payments under capital leases
2,016	287
2,017	101
Total	$ 388

Credit Agreement (Details)

Credit Agreement (Details) - USD ($) $ in Thousands	Dec. 30, 2014	Dec. 31, 2014	Feb. 28, 2014
Credit Agreement
Loss on extinguishment of debt		$ 372
Mednet
Credit Agreement
Amount of assumed debt associated with acquisition			$ 8,563
HSF
Credit Agreement
Percentage of capital stock of Cardiocore Lab Ltd. and BioTelemetry Belgium pledged to secure loan	65.00%
HSF | LIBOR
Credit Agreement
Debt instrument, basis spread on variable rate (as a percent)	4.00%
LIBOR floor (as a percent)	1.00%
HSF | Term Loan
Credit Agreement
Maximum borrowing capacity	$ 25,000
Additional uncommitted borrowing capacity	10,000
Loan balance net of original issue discount	23,194
Original issue discount	794
Deferred Long-term Liability Charges	74
HSF | Term Loan | April 2015 to December 2017
Credit Agreement
Principal amount of quarterly installment payments	312
HSF | Term Loan | January 2018 to September 2019
Credit Agreement
Principal amount of quarterly installment payments	625
HSF | Term Loan | October 2019 to December 2019
Credit Agreement
Remaining principal amount to be paid in full	16,563
HSF | Revolving Loan
Credit Agreement
Maximum borrowing capacity	$ 15,000
The Bancorp Bank
Credit Agreement
Aggregate amount of agreement with The Bancorp Bank			$ 9,830
Extinguishment of debt		$ 17,411

Employee Benefit Plan (Details)

Employee Benefit Plan (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Employee Benefit Plan
Employer's matching contribution as a percent of of the first 3% of employees' salary contributed	100.00%
Percentage of employees' salary contributed matched 100% by employer	3.00%
Employer's matching contribution as a percent of of the next 2% of employees' salary contributed	50.00%
Percentage of employees' salary contributed matched 50% by employer	2.00%
Employer's contribution	$ 1,786	$ 1,483	$ 0

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015USD ($)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2014USD ($)	Jun. 30, 2014USD ($)	Mar. 31, 2014USD ($)	Dec. 31, 2015USD ($)segment	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Segment information
Number of operating segments | segment									3
Revenues	$ 46,774	$ 43,492	$ 44,812	$ 43,435	$ 43,653	$ 43,113	$ 42,650	$ 37,162	$ 178,513	$ 166,578	$ 129,501
Income (loss) before income taxes									7,896	(12,106)	(7,104)
Depreciation and amortization									12,488	12,550	12,318
Capital expenditures									13,600	12,781
Healthcare
Segment information
Revenues									145,963	133,178	100,386
Income (loss) before income taxes											27,298
Depreciation and amortization											4,253
Capital expenditures									9,155	11,488
Research
Segment information
Revenues									21,853	19,744	20,329
Income (loss) before income taxes											798
Depreciation and amortization											4,057
Capital expenditures									4,373	1,077
Technology
Segment information
Revenues									10,697	13,656	8,786
Income (loss) before income taxes											5,307
Depreciation and amortization											551
Capital expenditures									72	216
Operating segments | Healthcare
Segment information
Revenues									7
Income (loss) before income taxes									44,559	27,792
Depreciation and amortization									7,790	8,157
Operating segments | Research
Segment information
Income (loss) before income taxes									540	(701)
Depreciation and amortization									3,676	3,710
Operating segments | Technology
Segment information
Revenues									10,224	7,789	6,191
Income (loss) before income taxes									4,390	6,681
Depreciation and amortization									371	502
Corporate and Other
Segment information
Revenues									(10,231)	(7,789)	(6,191)
Income (loss) before income taxes									(41,593)	(45,878)	(40,507)
Depreciation and amortization									$ 651	$ 181	$ 3,457

Legal Proceedings - CardioNet v

Legal Proceedings - CardioNet v. Mednet and MedTel Et Al Litigation (Details) $ in Thousands	Oct. 02, 2015USD ($)	Jan. 31, 2014patent	Mar. 31, 2015USD ($)	Jun. 30, 2014USD ($)	Dec. 31, 2015USD ($)	Dec. 31, 2014USD ($)	Dec. 31, 2013USD ($)
Legal proceedings
Professional Fees					$ 50	$ 669	$ 492
CardioNet v. Mednet and MedTel Et Al Litigation
Legal proceedings
Number of days to return materials	21 days
CardioNet v. Mednet and MedTel Et Al Litigation | CardioNet, LLC
Legal proceedings
Professional Fees	$ 975
Litigation settled | CardioNet v. Mednet and MedTel Et Al Litigation
Legal proceedings
Number of patents infringed by the defendants | patent		5
Litigation settled | CardioNet v. Mednet and MedTel Et Al Litigation | CardioNet, LLC
Legal proceedings
Lost profits and expenses settlement	$ 848
Civil Investigative Demand
Legal proceedings
Amount of non-operating charge				$ 6,400
Loss Contingency Accrual, Payments			$ 6,400

Legal Proceedings - CardioNet70

Legal Proceedings - CardioNet v. ScottCare Litigation (Details) $ in Thousands	May. 08, 2012patent	Dec. 31, 2015USD ($)
CardioNet v. ScottCare Litigation
Legal proceedings
Number of patents allegedly infringed | patent	5
CardioNet, Inc. and Braemar Manufacturing, LLC
Legal proceedings
Accrual of contingent liabilities | $		$ 0

Schedule II-Allowance for Dou71

Schedule II-Allowance for Doubtful Accounts (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Allowance for Doubtful Accounts
Beginning Balance	$ 10,662	$ 7,640	$ 7,617
Additions Charged To Expense	8,047	9,347	7,787
Deductions From Reserve	(7,108)	(6,325)	(7,763)
Ending Balance	$ 11,601	$ 10,662	$ 7,640